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Abstract
This chapter is devoted to the topics of not yet marketed HSV vaccine, which is still in
the focus of interest, especially from the point of immunotherapeutic use. To under‐
stand the principles of vaccination strategies (prophylactic and/or immunotherapeu‐
tic), the pathogenesis of herpes simplex virus 1 (HSV-1) and/or HSV-2 infections in
animal  models  is  briefly  outlined.  Even when both herpesviruses  may spread via
bloodstream, which is especially true in the immunocompromised host, the main route
of  their  transmission  is  along  peripheral  nerves.  Both  viruses  establish  latency  in
ganglion cells, and after reactivation, they spread along axons back to the site of primary
infection. Since neither the establishment of latency nor its reactivation can be fully
controlled by virus-neutralizing antibodies, the outcome of immune response greatly
depends on the activity of cytotoxic CD8+ T lymphocytes. The majority of important
antigenic epitopes is located in envelope glycoproteins (such as gB, gD, gE, gC and gG)
that are related to virus adsorption and penetration into susceptible cells. The HSV-1
and/or  HSV-2  experimental  vaccines  designed  so  far  were  either  purified  virion
products  derived  from  infected  cells  (subunit  vaccines),  purified  recombinant
immunogenic  herpes  simplex  virus  HSV-coded  proteins  (especially  gD),  and/or
attenuated live viruses lacking some of virulence tools (such as gH and/or gE). We bring
a comprehensive overview of the efficacy of experimental HSV-1/HSV-2 vaccines and
discuss our own data. In conclusion, we believe in the continued demand of HSV-1 and
HSV-2 vaccines, at least for their immunotherapeutic use, suggesting unified evalua‐
tion criteria for clinical trials to reach consent at their interpretation.
Keywords: herpes simplex virus 1 and herpes simplex virus 2, candidate vaccine, clin‐
ical trials, efficacy in animals, humoral and cell-mediated immune response, antigenic
epitopes
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1. Introduction
This review will be devoted to the topics of not yet marketed HSV vaccine(s), which design is
still in the focus of interest, especially from the point of view of immunotherapeutic use. The
human herpesvirus 1 (common name herpes simplex virus 1, HSV-1) is one of the first human
viruses discovered [1] and belongs among the most intensively investigated viruses. In the span
of the last 45 years, the PubMed portal has registered nearly 11,000 papers devoted to various
aspects of HSV-1/HSV-2, starting from virus structure, continued by the molecular mecha‐
nisms of lytic replication versus latency maintenance, through the virus spread in the body and
the eliciting of different forms of immune response, not omitting many clinical and epidemio‐
logical studies. In the second half of the last century, two subtypes of herpes simplex virus (HSV)
have been described [2] and were designated HSV type 1 and HSV type 2 [3]. While the former
(HSV type 1) has been predominantly isolated from the orofacial area and upper respiratory
airways, the latter was believed to infect the urogenital tract and occasionally the newborn.
According to recent classification, the HSV-2 represents a distinct species of the Simplexvirus
genus, which along with the Varicellovirus genus belongs to subfamily Herpesvirinae of the
Herpesviridae family. Nevertheless, both species are closely related, since they differ only in a
few antigenic domains (and/or epitopes) located in the envelope glycoproteins, namely, in an
entirely distinct gG and/or in the partially unrelated gC [4].
2. The molecular biology of HSV: virion structure, lytic replication and
latency
The HSV virion consists of four elements: (a) a core containing the viral DNA (vDNA), (b) an
icosahedral capsid surrounding the core, (c) an unstructured proteinaceous layer called the
tegument that surrounds the capsid, and (d) an outer lipid bilayer envelope exhibiting spikes
on its surface. The core contains the double-stranded (ds) DNA (dsDNA) genome wrapped as
a toroid or spool in a liquid crystalline state. A small fraction of the virion DNA may be circular,
but the bulk of packaged HSV DNA is linear and double-stranded. The enveloped virion is a
spherical particle with an average diameter of 186 nm, which might extend to 225 nm with the
spikes included, while the internal capsid has a constant diameter of 110 nm (reviewed at [5]).
The HSV virion contains more than 30 proteins that were designated as virion polypeptides
(VPs). Out of these approximately known and additional 10 suspected virion proteins (VPs),
at least 11 are located within the envelope at the surface of virion (predominantly accessible
to antibody), from which at least 10 are glycosylated (reviewed at [6]).
The HSV genes were classified into at least three general kinetic classes: alpha or immediate-
early (IE), beta or early (E), and gamma or late (L) genes. The IE mRNAs are transcribed by
the help of a transcription-inducing cofactor present in the virion tegument, also called alpha-
TIF/VP16. In brief, the tegument protein VP16 is becoming a part of a tripartite complex
comprised of octamer-binding protein 1 (Oct-1) and host cell factor 1 (HCF-1). At least two of
the IE proteins (ICP0 and ICP4; Figure 1) are transactivators needed for initiation of transcrip‐
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tion of the E/beta mRNAs (the first checkpoint) and later also for transcription of gamma/L
mRNAs. The latter are mainly structural virion proteins in contrast to E transcripts specify‐
ing nonstructural polypeptides. The structural proteins are transcribed in two waves, called
gamma1/L and gamma2/L. The former occurs more closely related with the E transcription
phase (second checkpoint) and requires predominantly ICP4. The expression of beta poly‐
peptides as well as that of group gamma1/L genes requires ICP4 and at low multiplicities of
infection also ICP0. The expression of gamma2/L genes, controlled at the third checkpoint,
requires ongoing DNA synthesis as well as the presence of ICP4 and ICP0 [7].
Figure 1. The IE genes and positions of their ORFs in the HSV genome.
The HSV genome consists of two covalently linked sequence components, designated as L
(long) and S (short). Each component consists of unique (U) sequences bracketed by invert‐
ed repeats (IR) [6].
The entry of HSV into cells involves the interaction of at least five virion surface glycopro‐
teins (gB, gC, gD, gH and gL) with several receptors on the cell surface following fusion of the
envelope with a cellular membrane. The HSV glycoproteins along with other proteins
important for pathogenicity are listed in Table 1. The first step in the process of entry is the
binding of virions to glycosaminoglycans (GAGs) on the cell surface. The interaction of virions
with GAGs is mediated by two glycoproteins: gC and gB. The next step in virus entry consists
of the interaction of gD with its receptors and execution of fusion between the envelope and
the cellular membrane by the heterodimer gH/gL and also by gB. The interaction of gD with
its receptors has been extensively studied in several laboratories. The consensus is that, for
entry, gD interacts with one of three natural receptors (reviewed at [8]). The receptors are
nectins, a protein-designated herpesvirus entry mediator (HVEM) and a selected form of 3-O-
sulfated heparan sulfate (3-OS HS). Nectins are intracellular adhesion molecules expressed on
epithelial and neural cells and are members of the extended immunoglobulin (Ig) family.
Earlier studies showed that gD of HSV-1 interacts with the amino-terminal V1 domain of
nectin 1. The wild-type HSV-2 can enter susceptible cells via an alternative receptor, namely,
nectin 2. HVEM is a member of the extended tumor necrosis factor receptor (TNFR) family,
expressed mainly on T lymphocytes but occasionally also on natural killer (NK) cells. Its
natural ligand is LIGHT (homologous to lymphotoxins, exhibits inducible expression), which
is constitutively expressed on T and natural killer (NK) cells and appears to be a regulator of
mucosal immune system. The LIGHT receptor competes with HVEM for the gD (reviewed
at [9]). The role of gD with respect to gB and gH/gL is to recruit and position them properly
to enable interaction with GAGs and with the lipid bilayers of the cellular membranes [10].
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Gene Protein Function
RL1 γ34.5 L protein, cofactor for ribosomal translation
RL2 ICP0 IE protein, spliced, three exons, a RING finger motif, acts as a nonspecific transactivator of any beta
and gamma gene
UL1 gL Late glycoprotein, forms the gH/gL complex, syn mutation
UL5 E class protein, part of the helicase/primase complex
UL9 E/L class, ori-binding protein, cooperates with ICP8 at initiation of vDNA replication
UL10 gM L class, glycosylated polypeptide, interacts with gN, participates in exocytosis and in cell-to-cell
spread
UL18 VP24 L class, capsid component, participates in triplex formation
UL19 VP5 L class protein, the major capsid component (149/150K)
UL21 L class tegument protein weakly capsid-associated, binds to microtubules at axonal transport
UL22 gH L class, glycosylated protein, essential for penetration to cells, needs complexing with gL
UL23 TK E class, tegument protein, thymidine kinase, virulence factor
UL26 L class, “scaffolding” capsid protein, the N-terminus required for virion assembly
UL27 gB L class glycoprotein, essential for adsorption and membrane fusion, syn3 locus
UL29 ICP8 E class, ssDNA binding, required for vDNA synthesis, keeping the DNA fork apart
UL30 DNA
pol
E/L class protein, DNA polymerase (elongation enzyme), virulence factor
UL35 VP26 L class virion protein, hexon component, also termed NC7
UL36 VP1/
VP2
L class, large tegument protein, important for egress through cytoplasm and re-envelopment
UL38 VP19C L class capsid protein, triplet component with VP23 (1:2), connects the hexons and pentons
UL39 RR E class protein, large subunit of RR, membrane-anchored protein kinase
UL40 RR E class protein, the small subunit of RR
UL41 vhs L class, tegument protein, interferes with the host cell proteosynthesis, virulence factor
UL44 gC L class, glycoprotein, reacts with GAG on cell surface, binds C3 and/or C5, virulence factor
UL48 Alpha-
TIF
/VP16
L class tegument protein, alpha-transinducing factor
UL49.5 gN L class membrane-associated small glycoprotein, complexes with gM
UL53 gK L class glycoprotein (40K), localizes to Golgi and ER, involved in egress, syn1 locus
UL54 ICP27/
IE63
IE class protein, blocks cellular mRNA transport to cytoplasm
RS1 ICP4 IE class protein, transactivator for E and L promoters
US1 ICP22 IE class regulatory protein, essential in animal experiments, cellular cyclin A and B degradation
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Gene Protein Function
US4 gG L class, glycosylated protein and envelope component, HSV-2 specific
US6 gD E/L class, glycosylated protein, 56K, adsorption to nectin 1 and HVEM protein receptors, essential
for entry to cells, neural uptake
US7 gI L class glycoprotein, forms heterodimer with gE, the complex facilitates cell-to-cell spread, neural
uptake
US8 gE L class glycoprotein, complexes with gI, essential for neural uptake
US12 ICP47 IE class protein, blocks the transport of viral antigenic epitopes
LAT Three categories of RNAs (8.5 kb, 2.0, and 1.5 kb), the small LATs terminate antisense to ICP0 ORF.
Latency regulator
Abbreviations: vDNA = viral DNA; ICP = infected cell protein; VP = virion protein (structural); IE = immediate-early
kinetics (class); E = early kinetics (class); L = late kinetics (class); K = 1,000 kDa (Mr); RR = ribonucleotide reductase; vhs
= virion host shutoff; LAT = latency-associated transcript(s); RNA molecules without capping, do not interact with
ribosomes; UL = unique long (DNA segment); US = unique short; RL = repeat long; RS = repeat short; HVEM = herpes
virus entry mediator)
aModified according to Roizman et al. [6].
Table 1. HSV-1 genes and corresponding proteins regarded for importance in virulencea.
The gB belongs to class III fusion protein that after GAG interaction facilitates fusion of the
virion envelope bilayer with the cellular membrane. A recent study showed that gB can also
bind to the paired immunoglobulin-like type 2 receptor-α (PILRα) to trigger viral fusion in
certain cell types; however, the precise role of this interaction in viral entry remains to be
determined [11]. The gH and gL appear to form a tight complex, since neither protein is stable
without the other. In contrast to gB, the structural studies of gH/gL showed no homology with
fusion domains of other viral glycoproteins. The exact role of gH/gL has not been deter‐
mined; however, one hypothesis is that the interaction of gD with its receptors changes the
conformation of gH/gL, which in turn induces gB to adopt its fusion conformation [12]. Even
that gE had been regarded for not essential in cell culture, it has been shown very important
at entering nerve endings (neural uptake) and subsequent neural spread [13].
The latency of HSV can be characterized by circularized state of the HSV genome in the absence
of IE and/or E transcription, especially lacking the expression of the two most important beta/
gamma transcription activators, namely, ICP0 and ICP4 (reviewed at [14]). We pointed at the
possibility that the IE block in question might be “leaky” since small amounts of ICP4 mRNA
could be found in the non-cultured ganglion explants which would later on yield infectious
virus [15]. Overwhelming literature deals with the hypotheses that the small latency-associ‐
ated transcripts RNA (LATs), RNA molecules expressed during latency contribute to the
silencing of ICP0 mRNA transcription as well as to the maintenance of latency [16]. It has been
shown that LAT can reduce the expression of viral genes and suppress HSV replication in
cultured cells. In addition, LAT probably protects the HSV DNA carrying neuron from
apoptosis. The anti-apoptosis activity of LAT has been independently confirmed in tissue
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culture and in the mouse ocular model [17]. Further data suggest the participation of LAT in
reactivation of the latent genome [18, 19].
3. Pathogenesis of HSV-1 and/or HSV-2 infections
The crucial event in HSV pathogenesis is, when the virus, which has reached the pseudouni‐
polar neuron of the regional sensory ganglion via the quick axonal transmission, may but need
not undergo productive replication. Thus, latency can be established from the very begin‐
ning, that is, in the absence of any transcription provided by the virus-coded alpha-transi‐
nducing factor (alpha-TIF). As described by Efstathiou et al. [20], the latent genome resides in
the nuclei of neurons in the form of a circularized nonintegrated plasmid-like structure. This
structure survives within the carrier neuron. the carrier neuron, so that neural cells harbor the
viral DNA for their lifetime. The tegument-bound alpha-transinducing factor (alpha-TIF)
might be “lost” during intra-axonal transport [21]. Some axons might be as long as 500 mm
(as a rule about 100 mm), while the minimum speed for HSV capsid transmission is about 1–
2 mm/h. The quick axonal transport along neurotubules is provided by the dynein molecule,
which binds the capsid component UL21. The environment within sensory neurons favors the
establishment of latency rather than productive virus replication also because the neuronal
transcription cofactors such as Oct-2 and/or Brn-3 repress the IE promoters [22, 23].
During reactivation, the blocked IE checkpoint of virus replication must be overcome
especially by overwhelming expression of ICP0 protein in order to achieve productive virus
replication and infectious HSV production [24]. The reactivation process can be hampered by
two different mechanisms. One depends on viral genome products interacting with cellular
cofactors of transcription within neurons. It may not be excluded that due to the existence of
at least two activation checkpoints, controlling the expression gamma1 or E/L proteins
(glycoproteins) and the gamma2/L proteins (glycoproteins), also incomplete virus particles
may be formed. The E and/or E/L proteins may be synthesized in the absence of complete
virion formation, or assembly of virions with defective vDNA occurs. However, the pres‐
ence of virus-coded antigens (even in the absence of infectious virus particles) could induce a
potent immune response (including the accumulation of cytotoxic T cells in the vicinity of HSV
carrier neurons). It should be also mentioned that the IE protein ICP47 acts by immune evasion.
Alternative effects inhibiting the antiviral defense can be exerted by gC [25], which binds
complement, and by the gE molecule, which binds the Fc fragment of immunoglobulins.
If reactivated virus reaches the peripheral tissues by retrograde axonal transport (skin
squamous epithelium, non-cornified squamous epithelium of mouth mucous membrane,
corneal epithelium), then it starts to replicate and causes inapparent virus shedding or blister
formation. A nice example for creating favorable conditions of virus replication at peripher‐
al skin was described in the ear model [26, 27]. These investigators found that prostaglan‐
dins produced after skin trauma or UV light irradiation would enhance the replication of
recurrent HSV-1. As shown by Walz et al. [28], neurectomy of the trigeminal nerve root
reactivated the latent HSV harbored within ganglion cells. The round trip of reactivated virus
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usually ends with reinfection of additional neurons within the regional sensory ganglion. Less
frequently, the retrograde axonal transport may continue in centripetal direction, that is, to
brain stem. Furthermore, the central nervous system (CNS) may become infected via blood‐
stream (in newborn) or along the olfactory route (reviewed at [29]).
The different manifestations of clinical disease reflect the above-described mechanisms of HSV
spread in the body. Essentially, HSV-1 can induce the acute primoinfection (gingivostomati‐
tis) and recurrent disease (classical labial herpes). Alternatively, the ocular herpes, often
manifested as herpes keratitis, occurs rather as recurrent disease than primoinfection. In
newborn as well as in the immunocompromised host and/or in the case of local inflamma‐
tion in the skin (e.g., due to allergic manifestations such as atopic eczema), the HSV might
cause generalized skin disease or even viral sepsis (i.e., the hepatoadrenal necrosis in new‐
born or severe meningoencephalitis). In newborn, perinatal infection causes an acute dissem‐
ination of HSV-2 via bloodstream. Meningitis and meningoencephalitis of neonates, similarly
as various forms of genital infection of man and women, are mainly HSV-2-related. In women,
the outer but also the inner genital tract (vagina or cervical mucosa covered with non-cornified
squamous epithelium) might become infected. In the skin as well as at the mucous mem‐
branes covered by squamous epithelium, both HSV-1 and HSV-2 species replicate within the
lower and/or medium squamous cell layers causing blister formation [30].
4. Mechanisms of the immune response to HSV-1 or HSV-2
The immune response to HSV-1 and/or HSV-2 is induced in an early and a late phase. During
early phase, the nonspecific antiviral mechanisms are activated, while in the late phase, the
HSV-specific reaction is mobilized. The specific immune response culminates by recruiting the
CD8+ cytotoxic T lymphocytes important for extracellular latency control, in contrast to the
intracellular latency control which has been discussed above. The specific cell-mediated
immune response may begin in the regional lymph nodes draining the virus inoculation site
(both T-lymphocyte lines are engaged) as well as in the trigeminal ganglia which harbor the
latent virus (mainly cytotoxic CD8+ T cells take part).
4.1. The innate immune response
The innate antiviral immunity to HSV-1 and/or HSV-2 is provided by alpha/beta type I
interferons (IFNs) as well as by activation of natural killer (NK) cells. The role of type I IFNs
in anti-HSV defense was demonstrated in knockout mice deficient in type I IFN production
[31, 32]. The type I IFN release is induced by virus constituents called pathogen-associated
molecular patterns (PAMPs) interacting with the corresponding pattern recognition recep‐
tors (PRRs) at the surface of responding cells. The best known examples are the Toll-like
receptors (TLR). For example, the envelope glycoprotein D molecule of the HSV-1 interacts
with the TLR-2 receptor on the target cell membrane [33], while the TLR-9 receptor binds to
non-methylated CpG motifs of the vDNA present in the nuclei of infected cells [34]. It has been
also shown that children with TLR-3 defects are more susceptible to herpes encephalitis [35,
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36]. Both types I of IFNs act on the receptors in neighboring cells eliciting the synthesis of
antiviral substances such as the 2′,5′-oligoadenylate synthase, RNase L, and/or RNA-depend‐
ent protein kinase. The type I IFN also inhibits cell proliferation and enhances the activation
of NK cells as well as the expression of MHC class I molecules, but downregulates MHC class
II expression. The type III IFNs, also designated as IFN-λ1, IFN-λ2 and IFN-λ3 (IL-29, IL-28A,
and IL-28B), have been recently characterized; alike to classical type I IFNs, also IFN-λ induces
production of antiviral substances in the infected cells [37]. The participation of type III IFNs
in inhibition of HSV replication has been confirmed in vitro [38, 39].
In addition to type I IFN formation, the activation of NK cells represents another important
arm of nonspecific immune response to HSV-1 and HSV-2 infection [40]. The nonspecific killers
belong to the group of class I innate lymphoid cells. Morphologically, they belong to large
granular lymphocytes (LGLs), which cytoplasm contains azurophilic granules with perfor‐
ins and granzymes A and B. They exert cytolytic activities helpful at the elimination of infected
cells. The perforins create a transmembrane channel piercing the cell membrane, while
granzymes activate the apoptosis of target cells. The NK cells also produce IFN-gamma, which
promotes their activation along with the activation of macrophages. In association with this,
enhanced death rates were noted in NK-deficient mice infected with HSV [41].
The elimination of HSV-1 and/or HSV-2 infected cells at the portal of entry is mediated by
additional immune cells such as neutrophils, dendritic cells (DCs), and macrophages. The
neutrophils secrete tumor necrosis factor (TNF) which induces apoptosis of infected cells via
caspase-8 activation [42]. Blood monocytes when entering the connective and/or other tissues
are altered into macrophages able to engulf the extracellular virus particles but also residues
of apoptotic cells. The active macrophages belong to the group of antigen-presenting cells
(APCs) that present the external immunogenic peptides to T lymphocytes. This process called
antigen presentation launches the specific immune response. Activated macrophages also
release several pro-inflammatory cytokines like TNF and IL-6 (participates in B-cell activa‐
tion), type I IFNs, and several chemokines such as RANTES regulated upon activation normal
T-cell expressed and secreted. Finally, nitric oxide (NO) and other substances are produced by
macrophages. It has been demonstrated in experiments in vitro that the replication of HSV-1
in infected cells may be considerably inhibited in the presence of NO released from macro‐
phages [43]. It should be mentioned here that IFN-gamma (belongs to type II IFNs) is in fact
a cytokine released from activated NK cells but also produced by the helper CD4+ T lympho‐
cytes as well as by cytotoxic CD8+ T lymphocytes [44]. The IFN-gamma considerably pro‐
motes function of activating macrophages and NK cells, in which it induces a production of
cytolytic substances. Taken together, both NK cells and macrophages represent an impor‐
tant first-line defense at the early stage of HSV infection, that is, before the onset of specific
immune response.
As already mentioned above, important immune cells participating in the initiation of antigen
processing are the dendritic cells (DCs). They represent a relatively heterogenous cell
population, from which the most active in antiviral defense are the myeloid (conventional)
and the plasmacytoid DCs (pDCs), both derived from the myeloid progenitor cells. The
myeloid DCs act as antigen-presenting cells (APCs), which carry the processed antigenic
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peptides into lymph nodes, where the peptides in question are presented to the T lympho‐
cytes. Based on this presentation event, the specific immune response is induced (activation
of T and B cells). In DC-depleted mice infected with HSV-1, encephalitis developed with a
significantly higher frequency as compared to conventional mice [45]. The plasmacytoid DCs
under physiological conditions participate in the development of peripheral immune
tolerance. Upon HSV infection, plasmacytoid DCs start to produce high amounts of IFN-alpha,
which not only inhibits the virus replication in the otherwise surrounding susceptible cells but
also activates lymphocytes and additional DCs. The HSV dsDNA binds to TLR-9 of the
plasmacytoid DC which initiates IFN-alpha production [46].
4.2. The acquired immune response
The acquired immune response encounters the activation of both T-lymphocyte lines, namely,
those differentiated either in direction of CD4+ or CD8+ T cells. The acquired immune response
then is triggered by the activation of T-cell receptors (TCRs), which recognize the HLA I/CD8
and/or the HLA II/CD4 bound antigenic peptides. While the former T cells are involved in the
destruction and elimination of HSV-infected cells, the latter acts as helper T cells at inducing
the specific antibody production by B cells. At primary infection, the HSV-1 or HSV-2 particles
are engulfed by DCs, which move the viral peptides to the regional lymph nodes, where the
naïve (unprimed) lymphocytes get first stimulated. The presentation of exogenous viral
peptides is achieved by means of the HLA class II molecules, which are recognized by the TCR
of the CD4+ T lymphocytes. In contrast, the immunogenic peptides of the newly (de novo)
synthesized HSV proteins are presented by HLA class I molecules at the surface of infected
cells where they interact with the TCR of cytotoxic CD8+ T lymphocytes [47]. In certain extent,
the so-called cross presentation occurs, at which the exogenous viral antigens are binding into
the HLA class I molecules that are recognized by the CD8+ T lymphocytes [48]. The activat‐
ed helper CD4+ T cells release cytokines such as IL-2 (inducing T-lymphocyte proliferation)
and IL-4, IL-5 and IL-6 (promoting the differentiation of B cells into plasma cells).
The plasma cells synthesize the specific virus-neutralizing antibodies reacting mainly with the
envelope glycoproteins such as gB and gD. The antibodies may also activate complement; on
the other hand, the gC molecule of the HSV-1 envelope binds C3b and in less extent also C5b
reducing the availability of complement components for virus neutralization. The low-
pathogenic HSV-1 gC minus strains may become pathogenic as was confirmed in a C3
knockout murine model [49]. The HSV-1 antibodies belong to IgM as well as IgG class; the
HSV-2 antibodies may be also of the secretory IgA class; the latter participates in virus
clearance at the genital tract mucosa [50]. Even though the serum antibodies are of impor‐
tance at the acute phase of infection, they may not fully eliminate the HSV since it invades the
nerve endings and spreads to regional sensory ganglia before the development of antibody
response. Some studies have shown that passive immunization with immune serum did not
prevent latency after genital infection with HSV-2 [51, 52, 53]. Since the latent HSV (episo‐
mal vDNA) is frequently harbored in neural tissue for lifelong, the presence of HSV antibod‐
ies in the serum of healthy subjects may be interpreted as infectious immunity.
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The cytotoxic CD8+ T lymphocytes represent the mainstream of the specific immune re‐
sponse providing clearance of HSV-1- or HSV-2-infected cells from the body. The activation
of cytotoxic CD8+ T cells takes place in the regional lymph nodes by means of viral antigenic
peptides presented by HLA class I molecules expressed at the surface of DCs. The IL-2 released
from helper T cells acts on the precursor cytotoxic T lymphocytes which differentiate into
mature cytotoxic CD8+ T cells. These mature CD8+ T cells accumulate at the peripheral virus
inoculation site, where they eliminate the HSV-infected cells. The activated cytotoxic T
lymphocytes release substances such as perforins, granzyme and granulysin, which destroy
the infected target cell and/or induce apoptosis acting on their FAS receptors. They also release
cytokines such as IFN-gamma and the tumor necrosis factor (TNF). IFN-gamma has a multiple
effect, since it enhances the expression of HLA class I as well as HLA class II molecules [54]
and also induces the expression of antiviral substances such as protein kinase R (PKR). This
substance causes inhibition of translation of many viral but also cellular proteins. The increased
TNF production also enhances the number and activity of HLA class I molecules.
The clearance of HSV-2 from peripheral tissues such as genital mucosa may be also provid‐
ed by CD4+ T cells. Transgenic mice, which revealed defects in their CD8+ T-lymphocyte
activity, have been still well protected against a lethal dose of HSV-2. In contrast, mice with
depleted CD4+ T lymphocytes showed slower clearance and less protection against HSV-2 [55–
57]. It can be concluded that the clearance of HSV-2 from genital mucosa requires coopera‐
tion of both the helper and cytotoxic T lymphocytes. Both T-cell populations can be found in
the skin, in the genital and oral mucosa, in the ocular tissue, and also in the trigeminal ganglia
surrounding the infected neurons [58–60].
After healing of the acute phase of HSV infection, about 0.1–1% of memory T cells, which may
remain within the circulation, are still able to recognize the HSV antigenic epitopes. These
epitopes being recognized by CD4+ and/or CD8+ lymphocytes were not all exactly mapped
yet, but until now, 22 of them were defined. The HSV-specific epitopes can be found mainly
among VPs (structural envelope glycoproteins, tegument proteins and capsid polypeptides),
but are also present on the ICPs, that is, on nonstructural enzymes and regulatory proteins.
The CD4+ T lymphocytes generated against the HSV-2-specified structural proteins recog‐
nize the epitopes of the RR1/UL39 polypeptide, the epitopes of UL46 tegument protein, and
several ones on glycoproteins gD and gB [61].
The CD8+ T lymphocytes, surrounding the neurons of the regional sensory ganglia of mice,
rabbits, and humans in which viral latency had been established [62–64], are believed to control
reactivation [65]. It was demonstrated, for example, that the ICP4/145K IE protein can be
digested by granzyme B, which would prevent virus reactivation [66]. The accumulated CD8+
T cells produce IFN-gamma as well, inhibiting the expression of ICP0/110K IE protein [67].
The most intriguing still unexplained question is why do the CD8+ T lymphocytes accumu‐
lated in the neighborhood of latent HSV-harboring neurons, since the expression of IE and E
polypeptides is widely hampered in them. Interestingly enough, the great majority of CD8+ T
lymphocytes in the trigeminal ganglion of mice in which latency had been established possess
a TCR which reacts with gB epitope at aa 498–505, while a smaller proportion of them may be
stimulated with RR1 epitope aa 822–829. The reactivity of the other T cells was not identified
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[68, 69]. In human trigeminal ganglia, both the CD4+ and CD8+ T cells were described that
react with many antigenic epitopes present in the IE polypeptides ICP0 and ICP4, in the E
polypeptides such as thymidine kinase (TK) and RRl, as well as with antigenic domains from
structural proteins such as the tegument proteins VP11/12 and VP13/14 and envelope
glycoproteins gB, gK, and gL, even though an exact identification of all antigenic epitopes in
the HSV proteins was not done yet [70, 71].
The phenotype of CD8+ T lymphocytes which can accumulate within the ganglia was not
characterized. The permanently present cytotoxic T lymphocytes might belong to the popu‐
lation of so-called tissue-resident memory T lymphocytes (TRM) or to the population referred
as T-effector memory cells (TEM cells). Additional markers such as CD44, CD69, CD62L, and
CCR7 were described at their surface, but their full definition is still the matter of investiga‐
tion [72].
5. Survey of experimental HSV-1 and HSV-2 vaccines and their design
Though the first vaccines against HSV-1 and/or HSV-2 were prepared in the sixties of last
century [73], no accepted and fully efficient HSV vaccine is available till now. The main
problem is the incomplete understanding of the role of cytotoxic CD8+ T cells in the mainte‐
nance and/or of elimination neurons carrying the silenced HSV DNA. Another serious problem
is the production of immune evasion polypeptides (reviewed at [74]). The optimal HSV vaccine
should overcome the ICP47-mediated interference with TAP, which transports the viral
peptides inside ER to bind with HLA molecules. Finally, the last but not negligible problem is
that at least some of over 20 immunogenic epitopes, which are distributed within about 80
HSV proteins (both structural and nonstructural), should participate in the vaccine but in an
optimal composition. An effective HSV vaccine might differ depending of its purpose, which
could be either preventive or immunotherapeutic. An ideal vaccine should not allow the acute
disease to develop, and it should be able to prevent the establishment of latency. These goals,
especially the latter, are difficult to achieve. The minimum effect provided by an immuno‐
therapeutic vaccine would be to minimize the extent of recurrent lesion originating from the
reactivation of the latent viral genome. As described above, the cytotoxic T lymphocytes
accumulating in vicinity of HSV DNA carrier cells in the regional sensory ganglion seem of
great importance when keeping a state of equilibrium probably inhibiting the transcription of
IE genes by an unknown mechanism. One could estimate that in the case of the inefficiency
and/or complete failure of the function of cytotoxic T-cell virus, reactivation and subsequent
retrograde axonal transport of virions occur. In this section, we describe the various HSV
vaccines which have been used under experimental conditions, while the next paragraph will
describe their efficacy in human volunteers.
5.1. Inactivated virion and subunit vaccines
The inactivated HSV-1 and/or HSV-2 vaccines consist of infected cell extracts, which have been
introduced in the 1980s of last century, partially purified and inactivated either by UV light,
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
187
by thermal treatment, or with formalin [75–77]. The efficacy of these first vaccines was tested
mainly in mice, but some of them were used also in human trials (see Section 6). Especially in
animal models, a good protective effect against acute virus challenge has been found not to
prevent the establishment of latency. However, when testing the effect of a virion-free HSV
vaccine prepared by extraction of infected LEP cells with Nonidet P-40 [78] in the rabbit corneal
model, Rajčáni et al. [79] concluded that even though vaccination prior to infection did not
fully prevent latency, it considerably reduced the number of regional sensory (trigeminal)
ganglion cells (neurons), which became the HSV genome carriers. Recently, a formalin-
inactivated HSV-2 (FI-HSV2) vaccine mixed with Al(OH)3 adjuvant was tested in combina‐
tion with monophosphoryl lipid A (MPL) [80]. The latter authors showed that the vaccine
protected mice against local vaginal challenge with HSV-2 as well as reduced the extent of
latency established in the sensory ganglia of lumbosacral nerve roots.
The subunit vaccines were mainly glycoprotein mixes purified on lectins (e.g., lentil lectin)
showing high affinity to the HSV virion envelope antigens. The dominant protective anti‐
gens among the 11 HSV glycoproteins are gB and gD, which possess important immunogen‐
ic epitopes. The abovementioned glycoproteins elicit virus-neutralizing antibodies, antibodies
participating in the antibody-dependent cellular cytotoxic (ADCC) response, and they also
activate the T lymphocytes. Several reports described the efficacy of the subunit vaccines of
various purity based on either HSV-1 and/or HSV-2 envelope glycoproteins [81–84]. For
example, the subunit HSV-1 vaccine (strain HSZP Immuno) had been prepared from chick
embryo cells infected with the low-virulent HSZP strain [85]. Tested in cooperation with the
Research and Development Department of the former Immuno AG Company in Vienna, the
infected cell extract in question was purified on lentil lectin to obtain a glycoprotein mix
containing at least four envelope glycoproteins (gB, gC, gD and gG). This subunit vaccine was
immunogenic and protective in mice as well as rabbits and showed at least partial cross
protection in the HSV-2-challenged guinea pigs infected by the vaginal route.
5.2. Recombinant HSV-1 and HSV-2 vaccines
The next step of HSV vaccine development proceeded from purified (nearly cell DNA-free)
subunit vaccines to those composed of recombinant HSV-1/HSV-2 polypeptides [86–90]. Great
majority of the recombinant vaccines contained the gB and/or gD polypeptides, and their
efficacy was done in mice. The first purified glycoprotein vaccines (gB1 and gD1) were
prepared on immunoaffinity columns (with specific-bound MoAbs); such vaccines were found
to protect mice against intracerebral challenge with HSV-1 [91–93]. Manservigi et al. [94]
expressed the gB ectodomain in mammalian cells. After immunization with the purified gB
fragment, the mice developed virus-neutralizing antibodies not only against HSV-1 but also
cross-reacting antibodies to HSV-2. In addition, the authors also showed that the animals were
resistant to the challenge with a lethal HSV dose. Later on, the recombinant proteins were
prepared by transfection of plasmids (carrying the gD and/or gB ORFs) into competent
Escherichia coli cells, which expressed the corresponding not glycosylated polypeptides [90,
95–100]. Recombinant glycoproteins (including gC) were also prepared in insect and/or
mammalian cells, in which the recombinant products could be glycosylated [101].
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Immunization with the recombinant gD1 or gD2 alone, or in combination with the gB protected
mice against infectious virus challenge given by intraperitoneal or subcutaneous routes and
in the case of gD1 vaccination cross protection to HSV-2 was observed as well. Immuniza‐
tion with gD alone was more effective than that with gB alone [87], while immunity provid‐
ed by gC alone was negligible [95]. In contrast, very high effect was achieved following
immunization with the mix of gB1, gD1, and gE1 glycoproteins in combination with the
Al(OH)3 adjuvant including the cross protection of guinea pigs challenged with HSV-2 at
genital route [99]. A trivalent vaccine containing gD2, gC2 and gE2 prepared in the baculovi‐
rus expression system was more immunogenic for mice than the subunit vaccine containing
gC2 and gD2 [102]. Furthermore, Awasthi et al. [103] immunized the guinea pigs with
recombinant proteins gC2 and gD2 prepared in a baculovirus system (which activated
antibody production), with the adenovirus vector carrying the VP5 capsid protein and with
the tegument proteins VP13 and VP14 (which activated the T-cell-mediated response).
However, no significant difference was detected, which confirmed that the glycoprotein mix
gD2/gB2 was sufficient enough.
The alum adjuvant in combination with the recombinant gD polypeptide activates the Th2-
type humoral response and therefore may be less suitable for immunotherapeutic use, for
which the Th1-type response is essential. To stimulate the Th1 response predominantly,
cytokines as adjuvants were tested, such as IL-2 with good results after corneal challenge with
the virulent HSV-1 CHR3 strain [104]. The so-called immune-stimulating lipid complexes
(ISCOM) combined with HSV-2 immunogenic polypeptides induced both Th1- and Th2-type
responses when showing a highly neutralizing antibody response along with the production
of IL-2, IFN-gamma, and TNF [105]. Similar strong potentiating effect was observed at
immunization with gD2 polypeptide adjuvanted with modified lipid A (AS04) [98]. Further‐
more, when using the gD2 fusion polypeptide along with MF59 (squalene) as adjuvant, the
local mucosa immune response could neither be stimulated properly, nor the latency reacti‐
vation prevented [106]. There is worth mentioning that the so-called autoimmune/inflamma‐
tory syndrome induced by adjuvants (ASIA) is an inflammatory syndrome associated with
certain adjuvants (such as MF59/squalene); the latter potentiates pathological autoimmune
reactions, which may be evident in the case of prophylactic mass immunization campaigns
[107].
In contrast to T-lymphocyte stimulation, the local IgA secretion can be enhanced by mistle‐
toe lectins such as ML-1, ML-2, and/or ML-3, the application of which in combination with the
gD2 polypeptide elicited a good secretory IgA response at intranasal challenge in mice [108].
The authors also used non-ionized liposome like particles carrying the gB ectodomain and
additional polylysine-rich polypeptides. Intranasal application of the product in question
provided protection against lethal challenge with HSV-2 and induced a strong Th1-type
immune response [109]. Skoberne et al. [110] prepared an experimental vaccine named
GEN-003/MM-2, which contained gD2 and the IE protein ICP4/175K expressed in a baculovi‐
rus system. In combination with MM2 adjuvants (also called matrix M2 composed of choles‐
terol, phospholipids, and saponin), the vaccine showed immunotherapeutic effect in guinea
pigs when it reduced the frequency of recurrent genital lesions upon HSV-2 challenge.
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5.3. Viral vectored and DNA vaccines
The recent idea of DNA vaccines represents a progressive approach for immunization
(reviewed at [111]). The advantage of DNA vaccines is that the immune response resembles
to that following the administration of live-attenuated virus vaccines, but without the risk of
reversion to viral phenotype. The viral DNA vaccines fall into two categories: viral DNA
carriers and the recombinant plasmid vaccines (classical DNA vaccines). The viral DNA
carriers are in fact nonpathogenic attenuated viruses that genome contains the inserted ORF
fragments encoding the desired antigen. The best examples are either the recombinant
adenovirus or vaccinia virus, which carry the HSV gD or gB genes. The latter glycoproteins
become expressed in the immunized animal, that is, in the mice, which are then protected
against HSV challenge [112–115]. The recombinant vesicular stomatitis virus (VSV) was
prepared from a plasmid containing the cDNA of the VSV RNA genome and the gD2 ORF
US6. This recombinant virus induced a good cell-mediated immune response as well as anti-
gD antibody formation. Immunized mice were protected against acute HSV-2 challenge, and
the establishment of latency was also reduced [116]. Chiuppesi et al. [117] described the effect
of immunization with feline lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycopro‐
tein B vaccine. This lentivirus construct induced HSV-1 antibody formation and also provid‐
ed cross protection against lethal HSV-2 infection.
Many classical plasmid DNA vaccines were prepared with the inserted HSV DNA fragment.
The majority of them encoded HSV-1 and/or HSV-2 glycoproteins such as gB, gD, gC, and gE;
their efficacy was tested in mice, guinea pigs, and rabbits [90, 118–124]. The results were
obtained after immunization with plasmids encoding the glycoproteins gD and/or gB of either
HSV-1 or HSV-2 alone or in combination. Especially the immunization of mice and/or guinea
pigs with the gD-expressing plasmid protected against challenge with a lethal dose of HSV-2
[124–128], but without clear-cut reduction of the latency rate. Better results were obtained with
plasmids encoding both gB and gD [119, 129, 130]. The efficiency of DNA vaccines could be
higher when adding cytokines such as IL-12 which induced the Th type 1 immune response
[131, 132] similarly as the presence of IL-18 and/or RANTES [133, 134]. In contrast, the Th2-
type response could be better achieved if the gD and IL-4-coding plasmid was used for
immunization [133, 135]. The Th type 2 immune response is important for virus clearance from
peripheral tissues including the infection of the eye, while the Th1-type response was involved
in preventing the latency establishment [135]. The DNA vaccine-encoding gB when com‐
bined with DNA plasmid coding for cytokines IL-12 and IL-18 as adjuvant was efficient in
prevention of the vaginal infection in mice: gB1/IL-12 and/or gB1/IL-18 elicited a local
resistance of genital mucosa and protected mice against lethal HSV-2 challenge. The best
results were observed with IL-12, while additional adjuvants did not enhance protection [136].
Another adjuvant tested with the DNA vaccines was the lipid adjuvant Vaxfectin®. In guinea
pigs immunized with plasmid-expressing gD2 and VP11/VP12 as well as VP13/14 polypepti‐
des along with a lipid adjuvant, a great prophylactic effect and the reduced HSV-2 replica‐
tion in the genital tract of experimental animals was observed. The vaccine also showed
immunotherapeutic properties when reducing the extent of latency (vDNA contents) in the
dorsal root ganglia [137, 138]. Immunization with the recombinant plasmid encoding the
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fusion protein consisting of the gB and the CCL19 chemokine ORF induced both the Th type
1 and the Th type 2 responses including an increased local secretory IgA antibody produc‐
tion protecting mice against HSV-2 challenge [139]. The enhanced efficiency of DNA vac‐
cines could be achieved by combining genes encoding the envelope glycoproteins with certain
nonstructural HSV genes. The recombinant plasmid consisting of gD2, gB2, and ICP27 ORFs
elicited a higher cellular as well as humoral response than the plasmid construct encoding the
glycoproteins only. The construct in question also provided a higher protection against vaginal
challenge with HSV-2 [140].
5.4. Live-attenuated HSV-1 and HSV-2 vaccines
Attenuated HSV vaccines are live HSV-1 and/or HSV-2 viruses derived from the wild-type
strains by modifications of their virulence but keep the immunogenic properties. The best
known deletion for HSV-1 was the removal of the UL22 ORF-encoding gH glycoprotein [141,
142] and/or the removal of the IR1 sequence encoding the protein γ34.5 gamma, a neuroviru‐
lence factor [143]. Furthermore, the deletion of the gE encoding by US8 gene, which is not
needed for virus replication in cell culture but is inevitable for neural uptake [144, 145] along
with the deletion of the UL41 gene, encoding the virion host shutoff (vhs) protein [146] might
be an excellent solution. In this respect, the non-virulent HSZP strain with natural mutations
altering the vhs protein, if deleted in the gE gene, would be of special advantage [147]. Another
attempts to prepare a live-attenuated HSV strain were made by deleting nonstructural genes,
such as the ORF UL54 (encodes the ICP27 IE polypeptide), the ORF RS1 (encodes the trans‐
activation protein ICP4) [146, 148], and/or the ORF RL2 (encoding the ICP0 transactivation
protein) as described by Halford et al. [149]. All the above-mentioned attenuated viruses was
protective against HSV challenge in various animal models. The HSV-2 deleted in the gH gene
designated as disabled infectious single cycle (DISC) and tested as therapeutic vaccine, but no
convincing protection was found [150].
Several other attenuated HSV strains were prepared by deleting the nonstructural genes
important for virulence. Deleted ORFs for such purpose were the following: (1) the UL23 ORF
encoding the thymidine kinase (TK) as described by Morrison and Knipe [151], (2) the UL39
ORF encoding the large RR1 subunit [152], (3) the UL29 ORF encoding the ssDNA-binding
ICP8 polypeptide [153], (4) the UL5 ORF encoding a protein of the primase/helicase complex
[154, 155], and finally (5) the UL9 ORF encoding the ori-binding protein [156]. The TK minus
recombinant R7017 was prepared from the w.t. strain F, which genome was, in addition,
deleted in the IR1 ORF sequence encoding the γ34.5 and furthermore manipulated by inserting
the gD2, gI2, and gG2 sequences along with a portion of the gE ORF (US4–US8). The TK-
reversed recombinant virus was further modified by reinserting the TK gene (R7020 TK plus).
Both recombinant viruses protected mice as well as guinea pigs against HSV-2 challenge [148].
The next UL39-/RR1-deleted virus was tested not only in animals but also in man [152, 157].
The phase I and phase II clinical trials showed partial protection against recurrences (in 37.5%
of immunized individuals as compared with the placebo group) [157]. The attenuated strain
deleted in the genes UL29 and UL5 (called dl29-5) protected mice against ocular infection with
HSV-1 and guinea pigs against genital challenge with HSV-2 [158, 159]. Stanfield et al. [160]
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prepared an attenuated strain of HSV-2 called VC2, which had mutations in the gK gene and
in the UL20 ORF (which is membrane protein inhibiting the neural uptake). This vaccine
prevented genital infection upon vaginal challenge with HSV-2 and also inhibited latent
infection in the lumbosacral dorsal root ganglia. Finally, the defective HSV-2 designated CJ9-
gD2 was used to immunize mice. This virus had mutation in the UL9 ORF which encodes a
vDNA replication protein and was deleted in the gD2 ORF (US9). The attenuated vaccine
induced a higher antibody response in comparison with the gD2-alum/MPL subunit vaccine
(used in a human trial) and protected mice against lethal challenge with HSV-2 [161].
6. Human vaccination trials: prophylactic and therapeutic HSV vaccines
Some of the vaccines mentioned above were tested not only in animal models but also in man
at clinical trials. They were designed either as prophylactic vaccines, or they were destined for
immunotherapeutic use, having been suggested for prevention or modulation of genital
infection predominantly caused by HSV-2. The aim of prophylactic vaccine against HSV-2
infection is not only to prevent a clinical disease at primoinfection but also to interfere with
the subsequent establishment of latency. The latter is a hard task, since the majority of vaccines
just reduce the number of neurons which are getting HSV DNA carriers but does not fully
prevent latent infection. Therefore, it is more reasonable to design a vaccine for immunother‐
apeutic use aimed to reduce the extent and the frequency of recurrent lesions.
The prophylactic vaccine should induce a satisfactory humoral as well as cell-mediated
immune response. For such purpose, subunit, recombinant and DNA vaccines were tested.
The first subunit vaccine tested was an HSV-2 glycoprotein mix (gB, gC, gG, gD, and gE)
purified from infected chick embryo cells (this product is essentially similar to the subunit
HSZP vaccine immuno mentioned above). As shown in 22 seronegative volunteers, this
particular vaccine induced both the humoral and the cell-mediated specific response [162].
Alternatively, a similar vaccine (containing gB2 and gG2) was used to immunize 161 seroneg‐
ative individuals with a less encouraging effect at phase II clinical trial [163]. The company
Chiron Corporation sponsored the testing of a recombinant gB2/gG2 vaccine mixed with the
MF59 adjuvant used for immunization of 137 persons. The efficiency of this vaccine was
reported 9% only [53, 164]. Another study by GlaxoSmithKline uses a recombinant gD2 in
combination with alum adjuvant and/or ASO4; in the latter trial, 7460 volunteers were selected
as seronegative before the onset of the phase II trial. Immunization with the vaccine in question
induced higher antibody titers than natural infection and also conferred partial protection
against natural infection that had a milder course as compared to non-immunized controls
[165]. At phase III trial, 847 seronegative individuals (no antibodies to HSV-1 as well as to
HSV-2) and 1867 women showing antibodies to HSV-1 but not to HSV-2 were immunized with
the same vaccine [166]. The results showed that 73–74% immunized women which were
seronegative against both antigens have been protected against HSV-2 primoinfection (as
detected by natural seroconversion), but the vaccine was not effective in man and in HSV-1
seropositive women. The GlaxoSmithKline company provided another trial, during which
together 8323 seronegative women (for HSV-1 as well as HSV-2) were immunized. This follow-
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up was less encouraging when showing only 20% efficiency when measured by the serocon‐
version rate against natural genital HSV-2 infection and about 58% protection against HSV-1
genital infection [167]. In a multicenter study from 2013, the possible role of the abovemen‐
tioned gD2-ASO4 vaccine in the etiology of stillbirth was evaluated. Together 19,727 preg‐
nant women were immunized, from which 13.3% really had stillbirth in comparison with
11.00% of pregnant women in the control group that shows a clearly not significant effect [168].
The HSV DNA vaccine was also tested for prophylactic use. In the phase I trial, 62 seronega‐
tive women were immunized with the gD2 recombinant plasmid GENEVAX. T-cell-mediat‐
ed response was found in one out of four volunteers [169]. Another prophylactic candidate
vaccine tested was the HSV-2/HSV529-attenuated virus (deleted in genes UL5 and and UL29,
also called dl5-29). This vaccine when tested in guinea pigs elicited a satisfactory humoral as
well as T-cell response, conferred protection to HSV-2 challenge, and reduced the extent of
latency in the regional lumbosacral ganglia [170]. The vaccine efficiency in human will be
evaluated by the end of 2016.
As already mentioned, the therapeutic vaccines should decrease the frequency of recurrence
episodes as well as their severity. To achieve this, the therapeutic vaccine must induce a potent
and specific T-cell-mediated response. Several subunit vaccines were tested with an immu‐
notherapeutic purpose, namely, the semipurified inactivated infected cell extracts, recombi‐
nant vaccines, and attenuated viruses. Probably, the first of the purified inactivated HSV-1-
infected cell extract tested was the vaccine by Kutinová et al. [171]. A similar vaccine introduced
by Skinner et al. [172] was used for immunization of 316 subjects with herpes disease who had
recurrent blisters at least six times per year. Though this vaccine induced a detectable increase
in the antibody levels and a satisfactory T-cell-mediated response, no difference in the
frequency of recurrences was noted during the 1-year observation period. However, the
vaccination accelerated the healing of the lesions, which had a less severe course in the
immunized persons. Among the recombinant vaccines tested in a therapeutic context, the gD2
vaccine containing alum adjuvant should be mentioned first. This was used for immuniza‐
tion of 98 HSV-2 seropositive persons who had at least four but up to 14 recurrence episodes
per year [173]. In this trial, the average of six recurrences per year in the placebo group was
siginificantly higher than the average of four recurrences per year in the immunized group
(p = 0.039). Furthermore, the gB2/gD2 vaccine mixed with the MF59 adjuvant was applied in
another trial, in which 202 volunteers were immunized. At the phase II clinical trial, no
difference was found in the titers of neutralizing antibodies during the observation period of
8 months, but there was a significant difference in the increased interval between the occur‐
rences of the recurrent lesions following the immunization procedure [174]. Further trials were
made using peptide vaccines. An overview of defined T-cell-based epitopes from HSV proteins
was reported by Laing et al. ([175], Table 2).
Not all known T-cell based epitopes can induce protective immunity. Mapping of T cells in
seropositive population found out that CD4+ T cells were mainly stimulated by tegument
proteins UL21, UL46, UL47, UL49 and envelope glycoproteins gB and gD. It was observed that
gB stimulates both CD4+ and CD8+ T cells, whereas gD induces stronger CD4+ T-cell-
dependent immunity [58]. CD8+ T cells were stimulated by gD53–61, gD70–78, and gD278–
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286 peptides mainly in HLA-A*02:01-positive HSV-1 and HSV-2 seropositive healthy
individuals [190]. Moreover, CD8+ T cells were also induced by tegument protein VP11/VP12
(gene UL46) that would account for another candidate protein to prepare effective HSV
vaccine [61].
Protein (gene) HSV-1 T-cell epitopes HSV-2 T-cell epitopes B-cell epitopes Reference
CD4 CD8 CD4 CD8
ICP0 (RL2) Human Human Human [61]
VP5 (UL19) Human Human [176]
gH I (UL22) Mice [69]
TK (UL23) Human [177]
VP26 (UL25) Human, mice Human [176, 178]
VP21 (UL26) Human Human [61]
gB (UL27) Human Human, mice Human Human Mice [60, 61, 179–181]
ICP8 (UL29) Human, mice Human [61, 176]
ICP10 (UL39) Human, mice Human Human [61, 69, 176]
Vhs (UL41) Human, mice [61, 69]
gC (UL44) Human, mice Mice [69, 180]
VP11/VP12 (UL46) Human Human, mice Human, mice [61, 176, 182]
VP13/VP14 (UL47) Human Mice Human, mice [61, 176, 178]
VP16 (UL48) Human Human [61, 183, 184]
VP22 (UL49) Human Human, mice Human, mice [61, 182, 183]
gK (UL53) Mice Human, mice [61, 185, 186]
ICP27 (UL54) Human Human, mice [61, 187]
ICP22 (US1) Human [61]
gG (US4) Mice Mice [69, 180]
gD (US6) Rabbit,
human
Rabbit, human,
mice
Human, mice Human, mice Mice [161, 180, 188–191]
gE (US8) Human Mice [178, 180]
ICP4 (RS1) Human Human Human [61, 192, 193]
aModified according to Laing et al. [175].
Table 2. Overview of T- and B-cell HSV-1/HSV-2–specific epitopes as tested in human, mice, and rabbitsa.
Vaccine design also requires involvement of epitopes suitable for HLA binding by most people.
In most ethnic groups, HLA-A*02:01 and HLA-B*07:02 belong to the most abundant HLA
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alleles [194]. HLA-A*02:01-restricted epitopes have been found in glycoprotein B (UL27 442–
451), tegument protein VP13/VP14 (UL47 551–559), and tegument protein coded for UL25
(UL25 372–380) of HSV-2, and they stimulated CD8+ T-cell response [176, 195]. HLA-B*07:02-
restricted epitopes have been reported for tegument protein VP22 (gene UL49) (HSV-2 UL49
49–57, HSV-2 UL49 82–90, HSV-2 UL49 99–108, HSV-2 UL49 131–140, and HSV-1 UL49 291–
290) and stimulated CD8+ T-cell response [176]. Samandary et al. [196] found association with
high prevalence of herpes infection and disease with the frequency of HLA-A*24, HLA-B*27,
and HLA-B*58 alleles. In contrast, low prevalence of herpes infection and disease appeared
associated with the high frequency of HLA-B*44 allele.
The effectivity of immune response is also depending on adjuvant type. Cooper et al. [189]
found out that vaccine design and adjuvant type can have a significant effect on T-cell epitope
utilization. Four epitopes within the gD2 molecule gD2 49–63, gD2 105–119, gD2 245–259 and
gD2 333–347 were administered to mice with alum or IL-12. CD4+ T-cell response was induced
in mice immunized with gD HSV-2 epitope gD2 245–259 and adjuvant alum. Mice immu‐
nized with IL-12 stimulate CD4+ T-cell response to HSV-2 epitope gD2 245–259 as well as to
gD2 333–347 [189].
“Epitope” (peptide) vaccines that selectively stimulate T and B cells belong to other herpes
simplex vaccine candidates. Wang et al. [180] prepared multi-epitope peptide vaccine that
contained six B-cell epitopes from different glycoproteins of HSV-2 (gB2 466–473, gC2 216–
223, gD2 6–18, gE2 483–491, gG2 572–579 and gI2 286–295), four CD4+ T-cell-based epitopes
(gD2 21–28, gD2 205–224, gD2 245–259 and gB2 162–177) and two CD8+ T-cell-based epito‐
pes (gD2 10–20 and gD2 268–276). All above-described epitopes were inserted into the
extracellular fragment (1–290) of HSV-2 glycoprotein D to construct multi-epitope assembly
peptides (MEAPs) by replacing some non-epitope amino acid sequences. The genes of the
selected peptides were inserted into recombinant plasmid and expressed in E. coli strain BL21.
The multi-epitope vaccine elicited in mice production of virus-neutralizing antibodies induced
Th1 and Th2 immune response and protected mice against intravaginally induced lethal
challenge of HSV-2 [180].
Many studies have focused on mapping of protective epitopes that stimulate immunity in
asymptomatic individuals, that is, individuals without clinical findings of herpes infection.
Analysis of IFN-γ-producing CD4+ T cells in HSV-1 seropositive individuals revealed that gB
peptide epitopes (aa 166–180 and aa 666–680) were strongly recognized by CD4+ T cells from
asymptomatic individuals, but not from symptomatic individuals. Inversely, CD4+ T cells
from symptomatic individuals preferentially recognized gB (aa 661–675) [179]. Another study
identified asymptomatic CD8+ T-cell epitopes from glycoprotein D (gD53–61, gD70–78 and
gD278–286) [191]. It can be hypothesized that repertoire of T-cell-based epitopes determines
either the development of HSV-1 (-2) clinical symptoms or asymptomatic viral shedding.
Finally, some investigators preferred the genetically attenuated virus vaccines, because they
induce an immune response essentially similar to that following natural infection. For
example, Casanova et al. [157] immunized the volunteers (32 persons having at least five
recurrent lesions per year) with an attenuated HSV-2 virus deleted in the UL39 gene (the RR1
protein ORF). The phase I and phase II clinical trials showed the reduction of recurrent clinical
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manifestations by 37.5% as compared with the placebo-immunized group. Another clinical
trial, which was performed in 2006, took the advantage of HSV-2-attenuated virus deleted in
the gH gene (the so-called disabled infectious single cycle [DISC] virus). Unfortunately, no
significant difference was found in the number of recurrences between the immunized and
control mock-immunized subjects during the 1 year follow-up period [150]. The last phase I
and II clinical trial which results will be announced nowadays concerns volunteers who had
from two to nine recurrent lesions per year; they were immunized with a DNA vaccine-
expressing gD2 in combination with the lipid adjuvant Vaxfectin [197].
7. Future perspectives of HSV-1/HSV-2 vaccination with the emphasis on
the T-cell response
As described above, an effective vaccine against HSV-1 and HSV-2 infection that would
prevent virus reactivation (therapeutic vaccine) should stimulate both humoral and cellular
immunity mediated by CD4+ and CD8+ T cells. This immune response can be induced by live-
attenuated virus, but such viruses are not safe because of their possible reversion back to the
wild-type virus. Therefore, alternative approaches to develop effective herpes simplex vaccine
have been attempted during the last decades. Nowadays, T-cell-inducing herpes simplex
vaccines bearing “asymptomatic” immunodominant epitopes derived from HSV proteins
were designed and tested [180]. Such vaccines possess many advantages over traditional
vaccine like (1) induction of specific T-cell-based immunity, (2) inhibition of pathogenic
immune response, and (3) safety.
Only few asymptomatic T-cell epitope-based vaccines were prepared and tested until now.
The vaccine used by Wald et al. [198] contained 32 synthetic immunogenic HSV-2 peptides,
linked to the heat shock protein Hsp 70 in combination with the QS-21 (contains a saponin)
adjuvant. In 32 immunized volunteers, the vaccine elicited no complication, but induced a
satisfactory CD4+/CD8+ T-lymphocyte response against a wide range of immunogenic HSV-2
peptides used in the stimulation tests in vitro. Chentoufi et al. [191] prepared CD8+ T-cell
epitope-based vaccine containing three separate pairs of CD4–CD8 lipopeptides. Each of the
lipopeptide contained one of the three asymptomatic immunodominant human CD8+ T-cell
peptide epitopes from HSV-1 glycoprotein D (gD53–61, gD70–78, and gD278–286) that were
joined with a human CD4+ T-cell peptide epitope (gD49–82). Humanized HLA-A*02:01
transgenic rabbits were immunized with a mixture of the three CD4–CD8 HSV-1 gD lipopep‐
tides. Immunization induced an increased production of CD4+ and CD8+ T cells and protect‐
ed rabbits against ocular HSV disease [191]. The same ASYMP vaccine was used for therapeutic
vaccination of HLA transgenic rabbits infected by HSV-1. The vaccine induced production of
HSV-specific CD8+ T cells that prevent HSV-1 reactivation ex vivo from latently infected
explanted trigeminal ganglia. Moreover, the vaccine significantly reduced HSV-1 shedding
and boosted the function of HSV-1 gD epitope-specific CD8+ T cells in draining lymph nodes,
conjunctiva, and trigeminal ganglion [199].
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The lipopeptide vaccines belong to another herpes simplex vaccine candidate. The lipopep‐
tide vaccine can be easily produced and possesses some advantages over traditional vaccine
such as safety and tolerance, bearing protective T-cell epitopes derived from HSV antigens,
missing of non-immunogenic harmful epitopes, and missing of viral pathogenic proteins such
as ICP47, and lipids have functioned as adjuvant. Previous studies observed that lipopep‐
tide vaccine injected intranasally into mice induced mucosal and systemic B and Th1 im‐
mune response [191]. Other authors prefer attenuated genetically modified herpes simplex
viruses as successfully vaccine candidates (Section 5.4).
8. Conclusions
In conclusion, the development of successfully therapeutical vaccine against HSV infection
should respect the following recommendations: (1) the assessment of putative differences in
the recognition of T- and/or B-cell epitopes from envelope, tegument, and regulatory HSV
proteins in patients with recurrent herpes disease versus asymptomatic individuals; (2) the
production of new safer adjuvants avoiding those claimed to cause the ASIA syndrome; (3)
the induction of local mucosal immunity mediated by lipopeptides; (4) the use of human‐
ized susceptible HLA transgenic mice as well as rabbits before human trials; and (5) at last but
not least, the efficacy of human trials for an immunotherapeutic vaccine that should be made
according to internationally accepted unified criteria in at least three groups of subjects
(seronegative individuals, seropositive individuals without recurrent herpes disease, and
volunteers with such disease). The tests should include the demonstration of elevated antibody
titers after vaccination and in vitro testing of the T-lymphocyte response in a blastic transfor‐
mation test as well as production of selected cytokines; 6. Finally, the application of the
therapeutic vaccine in future human trials should be intracutaneous rather than by using other
administration routes.
Author details
Vladimíra Ďurmanová1, Marian Adamkov2 and Július Rajčáni3*
*Address all correspondence to: viruraj@savba.sk
1 Institute of Immunology, Faculty of Medicine, Comenius University in Bratislava, Bratislava,
Slovakia
2 Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius Uni‐
versity, Martin, Slovakia
3 Institute of Virology, Slovak Academy of Sciences, Bratislava, Slovakia
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
197
References
[1] Gruter W. Das Herpesvirus, seine aetiologische und klinische Bedeutung. Munch Med
Wsch 1924, 71: 1058.
[2] Schneweis KE. Untersuchungen zur Typendifferenzierung des Herpesvirus hominis.
Z Immun-Forsch 1962, 124: 24–28.
[3] Wildy P. Classification and nomenclature of viruses, pp. 33–34, In: Monographs in
Virology, Melnick JL (ed), Karger, Basel, 1971.
[4] Lee EK, Coleman RM, Pereira L, Bailey PD, Tatsuno M, Nahmias AJ. Detection of herpes
simplex virus type 2 specific antibody with glycoprotein G. J Clin Microbiol 1985, 22:
641–644.
[5] Liu F, Zhou ZH. Comparative virion structures of human herpesviruses, pp. 27–43, In:
Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R and
Yamanishi K (eds). Human Herpesviruses: Biology, Therapy and Immunoprophylax‐
is. Cambridge University Press, 2007.
[6] Roizman B, Knipe DM, Whitley RJ. Herpes Simplex Viruses, pp. 1823–1897, In: Knipe
DM, Howley PM (eds) Fields Virology, 6th ed., Walters Cluver/Lippincott Williams
and Wilkins, Philadelphia, 2013.
[7] Knipe DM, Cliffe AR. Chromatin control of herpes simplex virus lytic and latent
infection. Nat Rev Microbiol 2008, 6: 211–221. doi: 10.1038/nrmicro1794.
[8] Campadelli-Fiume G, Menotti L, Avitabile E, Gianni T. Viral and cellular contribu‐
tions to herpes simplex virus entry into the cell. Curr Opin Virol 2012, 2: 28–36. doi:
10.1016/j.coviro.2011.12.001.
[9] Rajčáni J, Vojvodová A. The role of herpes simplex virus glycoproteins in the virus
replication cycle. Acta Virol 1998, 42: 103–118.
[10] Gianni T, Amasio M, Campadelli-Fiume G. Herpes simplex virus gD forms distinct
complexes with fusion executors gB and gH/gL in part through the C-terminal
profusion domain. J Biol Chem 2009, 284: 17370–17382. doi: 10.1074/jbc.M109.005728.
[11] Satoh T, Arii J, Suenaga T, Wang J, Kogure A, Uehori J, Arase N, Shiratori I, Tanaka S,
Kawaguchi Y, Spear PG, Lanier LL, Arase H. PILRα is a herpes simplex virus-1 entry
co-receptor that associates with glycoprotein B. Cell 2008, 132: 935–944. doi: 10.1016/
j.cell.2008.01.043.
[12] Stampfer SD, Lou H, Cohen GH, Eisenberg RJ, Heldwein EE. Structural basis of local,
pH dependent conformational changes in glycoprotein B from herpes simplex virus
type 1. J Virol 2010, 84: 12.924–12.933. doi: 10.1128/JVI.01750-10.
Herpesviridae198
[13] Dingwell KS, Brunetti CR, Hendricks RL, Tang Q, Tang M, Rainbow AJ, Johnson DC.
Herpes simplex virus glycoprotein E and I facilitate cell to cell spread in vivo and across
junctions of cultured cells. J Virol 1994, 68: 834–845.
[14] Rajčáni J, Ďurmanová V. Early expression of herpes simplex virus (HSV) proteins and
reactivation of latent infection. Folia Microbiol 2000, 45: 7–28
[15] Režuchová I, Kúdelová M, Ďurmanová V, Vojvodová A, Košovský J, Rajčáni J.
Transcription at early stages of herpes simplex virus 1 infection and during reactiva‐
tion. Intervirology 2003, 46: 25–34.
[16] Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. RNA complementary to
a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science
1987, 235: 1056–1059.
[17] Ahmed MM, Lock C, Millerm G. Regions of the herpes simplex virus type 1 latency-
associated transcript that protect cells from apoptosis in vitro and protect neuronal cells
in vivo. J Virol 2002, 76: 717–722.
[18] Perng GC, Jones C, Ciacci-Zanella J, Stone M, Henderson G, Yukht A, Slanina SM,
Hofman FM, Ghiasi H, Nesburn AB, Wechsler SL. Virus induced neuronal apoptosis
blocked by the herpes simplex virus latency associated transcript (LAT). Science 2000,
287: 1500–1503.
[19] Perng GC, Maguen B, Jin L, Mott KR, Osorio N, Slanina SM, Yukht A, Ghiasi H, Nesburn
AB, Inman M, Henderson G, Jones C, Wechsler SL. A gene capable of blocking
apoptosis can substitute for herpes simplex virus type 1 latency associated transcript
gene and restore wild type reactivation levels. J Virol 2002, 76: 1224–1235
[20] Efstathiou S, Minson AC, Field HJ, Anderson JR, Wildy P. Detection of herpes simplex
virus specific DNA sequences in latently infected mice and in humans. J Virol 1986, 32:
446–455.
[21] Kristie TM and Roizman B. Differentiation and DNA contact points to the host proteins
binding at the cis site of for virion-mediated induction of herpes simplex virus 1 alpha
genes. J Virol 1988, 62: 1145–1157
[22] Lillycrop KA, Budrahan VS, Lakin ND, Terrenghi G, Wood JN, Polak JM, Latchman
DS. A novel POU family transcription factor is closely related to Brn-3 but has a distinct
expression pattern in neuronal cells. Nucleic Acids Res 1992, 20: 5093–5096.
[23] Lillycrop KA, Estridge JK, Latchman DS. Functional interaction between different
isoforms of the Oct-2 transcription factor expressed in neuronal cells. Biochem J 1994,
298: 245–248.
[24] Preston CM, Efstathiou S. Molecular basis of HSV latency and reactivation, pp. 602–
615, In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R,
Yamanishi K. (eds.) Human Herpesviruses, Biology, Therapy and Immunoprophylax‐
is, Cambridge University Press, 2007.
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
199
[25] Fries LF, Friedman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM. Glyco‐
protein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J
Immunol 1986, 137: 1636–1641.
[26] Hill TJ, Field HJ, Blyth WA. Acute and recurrent infection with herpes simplex virus
in the mouse: a model for studying latency and recurrent disease. J Gen Virol 1975, 28:
341–353.
[27] Hill TJ, Blyth HJ. An alternative theory of herpes simplex recurrence and a possible role
for prostaglandins. Lancet 1976, 1: 397–398.
[28] Walz M, Price R, Notkins A. Latent ganglionic infection with herpes simplex virus
types 1 and 2: viral reactivation after neurectomy. Science 1974, 184: 1185–1187.
[29] Kúdelová M, Rajčáni J. Herpes simplex virus and human CNS infection, pp. 169–214,
In: Singh SK, Ružek D. (eds), Neuroviral Infection, 1st ed., Taylor and Francis Group
CRC, 2013.
[30] Whitley R, Kimberlin D, Prober Ch. HSV 1 and 2: pathogenesis and disease. pp. 569–
601, In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R,
Yamanishi K. (eds.). Human Herpesviruses, Biology, Therapy and Immunoprophy‐
laxis, Cambridge University Press, 2007.
[31] Svensson A, Bellner L, Magnusson M, Eriksson K. Role of IFN-alpha/beta signaling in
the prevention of genital herpes virus type 2 infection. J Reprod Immunol 2007, 74: 114–
123.
[32] Conrady CD, Halford WP, Carr DJ. Loss of the type I interferon pathway increases
vulnerability of mice to genital herpes simplex virus 2 infection. J Virol 2011, 85: 1625–
1633. doi: 10.1128/JVI.01715-10.
[33] Kim M, Osborne NR, Zeng W, Donaghy H, McKinnon K, Jackson DC, Cunningham
AL. Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitat‐
ing their presentation to CD4 T lymphocytes. J Immunol 2012, 188: 4158–4170. doi:
10.4049/jimmunol.1103450.
[34] Lundberg P, Welander P, Han X, Cantin E. Herpes simplex virus type 1 DNA is
immunostimulatory in vitro and in vivo. J Virol 2003, 77: 11158–11169.
[35] Guo Y, Audry M, Ciancanelli M, Alsina L, Azevedo J, Herman M, Anguiano E, Sancho-
Shimizu V, Lorenzo L, Pauwels E, Philippe PB, Pérez de Diego R, Cardon A, Vogt G,
Picard C, Andrianirina ZZ, Rozenberg F, Lebon P, Plancoulaine S, Tardieu M, Valérie
D, Jouanguy E, Chaussabel D, Geissmann F, Abel L, Casanova JL, Zhang SY. Herpes
simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is
otherwise redundant in protective immunity. J Exp Med 2011, 208: 2083–2098. doi:
10.1084/jem.20101568.
[36] Herman M, Ciancanelli M, Ou YH, Lorenzo L, Klaudel-Dreszler M, Pauwels E, Sancho-
Shimizu V, Pérez de Diego R, Abhyankar A, Israelsson E, Guo Y, Cardon A, Rozen‐
Herpesviridae200
berg F, Lebon P, Tardieu M, Heropolitanska-Pliszka E, Chaussabel D, White MA, Abel
L, Zhang SY, Casanova JL. Heterozygous TBK1 mutations impair TLR3 immunity and
underlie herpes simplex encephalitis of childhood. J Exp Med 2012, 209: 1567–1582.
doi: 10.1084/jem.20111316.
[37] Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interfer‐
on (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent
antiviral activity against select virus infections in vivo. J Virol 2006, 80: 4501–4509.
[38] Li J, Hu S, Zhou L, Ye L, Wang X, Ho J, Ho W. Interferon lambda inhibits herpes simplex
virus type I infection of human astrocytes and neurons. Glia 2011, 59: 58–67. doi:
10.1002/glia.21076.
[39] Lopušná K, Režuchová I, Kabát P, Kúdelová M. Interferon lambda induces antiviral
response to herpes simplex virus 1 infection. Acta Virol 2014, 58: 325–332.
[40] Grubor-Bauk B, Arthur JL, Mayrhofer G. Importance of NKT cells in resistance to
herpes simplex virus, fate of virus-infected neurons, and level of latency in mice. J
Virol 2008, 82: 11073–11083. doi: 10.1128/JVI.00205-08.
[41] Adler H, Beland JL, Del-Pan NC, Kobzik L, Sobel RA, Rimm IJ. In the absence of T cells,
natural killer cells protect from mortality due to HSV-1 encephalitis. J Neuroimmu‐
nol 1999, 93: 208–213.
[42] Milligan GN. Neutrophils aid in protection of the vaginal mucosae of immune mice
against challenge with herpes simplex virus type 2. J Virol 1999, 73: 6380–6386.
[43] Kodukula P, Liu T, Rooijen NV, Jager MJ, Hendricks RL. Macrophage control of herpes
simplex virus type 1 replication in the peripheral nervous system. J Virol 1999, 162:
2895–2905.
[44] Buc M. Interferon gamma (IFN-gamma), p. 95, In: Basic and Clinical Immunology,
Comenius University, Bratislava, 2008.
[45] Kassim SH, Rajasagi NK, Zhao X, Chervenak R, Jennings SR. In vivo ablation of CD11c-
positive dendritic cells increases susceptibility to herpes simplex virus type 1 infec‐
tion and diminishes NK and T-cell responses. J Virol 2006, 80: 3985–3993.
[46] Hochrein H, Schlatter B, O'Keeffe M, Wagner C, Schmitz F, Schiemann M, Bauer S,
Suter M, Wagner H. Herpes simplex virus type-1 induces IFN-alpha production via
Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci U S
A 2004, 101: 11416–11421.
[47] den Haan JM, Bevan MJ. Antigen presentation to CD8+ T cells: cross-priming in
infectious diseases. Curr Opin Immunol 2001, 13: 437–441.
[48] Ramirez MC, Sigal LJ. The multiple routes of MHC-I cross-presentation. Trends
Microbiol 2004, 12: 204–207.
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
201
[49] Lubinski J, Wang L, Mastellos D, Sahu A, Lambris JD, Friedman HM. In vivo role of
complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp
Med 1999, 190: 1637–1646.
[50] McDermott MR, Brais LJ, Evelegh MJ. Mucosal and systemic antiviral antibodies in
mice inoculated intravaginally with herpes simplex virus type 2. J Gen Virol 1990, 71:
1497–1504.
[51] Dudley KL, Bourne N, Milligan GN. Immune protection against HSV-2 in B-cell-
deficient mice. Virology 2000, 270: 454–463.
[52] Morrison LA, Zhu L, Thebeau LG. Vaccine-induced serum immunoglobin contrib‐
utes to protection from herpes simplex virus type 2 genital infection in the presence of
immune T cells. J Virol 2001, 75: 1195–1204.
[53] Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr., Hands‐
field HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL,
Burke RL, Leong WP, Straus SE. Recombinant glycoprotein vaccine for the preven‐
tion of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine
Study Group. JAMA 1999, 282: 331–340.
[54] Handunnetthi L, Ramagopalan SV, Ebers GC, Knight JC. Regulation of major histo‐
compatibility complex class II gene expression, genetic variation and disease. Genes
Immun 2010, 11: 99–112. doi: 10.1038/gene.2009.83.
[55] Milligan GN, Bernstein DI. Interferon-gamma enhances resolution of herpes simplex
virus type 2 infection of the murine genital tract. Virology 1997, 229: 259–268.
[56] Milligan GN, Bernstein DI, Bourne N. T lymphocytes are required for protection of the
vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes
simplex virus type 2. J Immunol 1998, 160: 6093–6100.
[57] Gill N, Ashkar AA. Overexpression of interleukin-15 compromises CD4-dependent
adaptive immune responses against herpes simplex virus 2. J Virol 2009, 83: 918–926.
doi: 10.1128/JVI.01282-08.
[58] Koelle DM, Schomogyi M, McClurkan C, Reymond SN, Chen HB. CD4 T-cell respons‐
es to herpes simplex virus type 2 major capsid protein VP5: comparison with respons‐
es to tegument and envelope glycoproteins. J Virol 2000, 74: 11422–11425.
[59] Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, Wald A, Corey L. Virus-
specific CD8+ T cells accumulate near sensory nerve endings in genital skin during
subclinical HSV-2 reactivation. J Exp Med 2007, 204: 595–603.
[60] Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-
specific memory CD8+ T cells are selectively activated and retained in latently infected
sensory ganglia. Immunity 2003, 18: 593–603.
[61] Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Dong L, Marshak JO, McClurkan CL,
Yamamoto TN, Bailer SM, Laing KJ, Wald A, Verjans GM, Koelle DM. Cross-presen‐
Herpesviridae202
tation and genome-wide screening reveal candidate T cells antigens for a herpes
simplex virus type 1 vaccine. J Clin Invest 2012, 122: 654–763. doi: 10.1172/JCI60556.
[62] Gebhardt BM, Hill JM. Cellular neuroimmunologic responses to ocular herpes simplex
virus infection. J Neuroimmunol 1990, 28: 227–236.
[63] Liu T, Tang Q, Hendricks RL Inflammatory infiltration of the trigeminal ganglion after
herpes simplex virus type 1 corneal infection. J Virol 1996, 70: 264–271 (1996).
[64] Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL. CD8(+) T cells can block herpes
simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp
Med 2000, 191: 1459–1466.
[65] Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O, Strupp M, Arbu‐
sow V, Brandt T. Latent herpesvirus infection in human trigeminal ganglia causes
chronic immune response. Am J Pathol 2003, 163: 2179–2184.
[66] Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL.
Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from
neuronal latency. Science 2008, 322: 268–271. doi: 10.1126/science.1164164.
[67] Decman V, Kinchington PR, Harvey SA, Hendricks RL. Gamma interferon can block
herpes simplex virus type 1 reactivation from latency, even in the presence of late gene
expression. J Virol 2005, 79: 10339–10347.
[68] Mueller SN, Heath W, McLain JD, Carbone FR, Jones CM. Characterization of two TCR
transgenic mouse lines specific for herpes simplex virus. Immunol Cell Biol 2002, 80:
156–163.
[69] St Leger AJ, Peters B, Sidney J, Sette A, Hendricks RL. Defining the herpes simplex
virus-specific CD8+ T cell repertoire in C57BL/6 mice. J Immunol 2011, 186: 3927–3933.
doi: 10.4049/jimmunol.1003735.
[70] Derfuss T, Segerer S, Herberger S, Sinicina I, Hüfner K, Ebelt K, Knaus HG, Steiner I,
Meinl E, Dornmair K, Arbusow V, Strupp M, Brandt T, Theil D. Presence of HSV-1
immediate early genes and clonally expanded T-cells with a memory effector pheno‐
type in human trigeminal ganglia. Brain Pathol 2007, 17: 389–398.
[71] van Velzen M, Jing L, Osterhaus AD, Sette A, Koelle DM, Verjans GM. Local CD4 and
CD8 T-cell reactivity to HSV-1 antigens documents broad viral protein expression and
immune competence in latently infected human trigeminal ganglia. PLoS Pathog 2013,
9: e1003547. doi: 10.1371/journal.ppat.1003547.
[72] Egan KP, Wu S, Wigdahl B, Jennings SR. Immunological control of herpes simplex virus
infections. J Neurovirol 2013, 19: 328–345. doi: 10.1007/s13365-013-0189-3.
[73] Kern A, Schiff B. Vaccine therapy in recurrent herpes simplex. Arch Dermatol 1964, 89:
844–845.
[74] Koelle D. HSV 1 and 2 immunobiology and host response, pp. 616–641, In: Arvin A,
Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (eds).
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
203
Human Herpesviruses: Biology, Therapy and Immunoprophylaxis. Cambridge
University Press, 2007.
[75] Skinner GR, Buchan A, Hartley CE, Turner SP, Williams DR. The preparation, efficacy
and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes
simplex virus infections in human subjects. Med Microbiol Immunol 1980, 169: 39–51.
[76] Dundarov S, Andonov P, Bakalov B, Nechev K, Tomov C. Immunotherapy with
inactivated polyvalent herpes vaccines. Dev Biol Stand 1982, 52: 351–358.
[77] Scriba M. Animal studies on the efficacy of vaccination against recurrent herpes. Med
Microbiol Immunol 1982, 171: 33–40.
[78] Kutinová V, Vonka V, Řezáčová D. Production and some properties of antigen extracts
for neutralizing of herpes simplex virus. Acta Virol 1977, 19: 189–197.
[79] Rajčáni J, Kutinová L, Vonka V. Restriction of latent herpes virus infection of rabbits
immunized with subviral herpes simplex virus vaccine. Acta Virol 1980, 24: 183–193.
[80] Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH. Inactivated
HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital
infection and shedding following long term challenge and rechallenge. Vaccine 2012,
30: 6541–6550. doi: 10.1016/j.vaccine.2012.08.049.
[81] Dundarov S, Andonov P. Seventeen years of application of herpes vaccines in Bulgaria.
Acta Virol 1994, 38: 205–208.
[82] Hilfenhaus J, Christ H, Köhler R, Moser H, Kirchner H, Levy HB. Protectivity of herpes
simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the
dependence of protection on T cell competence. Med Microbiol Immunol 1981, 169:
225–235.
[83] Thomson TA, Hilfenhaus J, Moser H, Morahan PS. Comparison of effects of adju‐
vants on efficacy of virion envelope herpes simplex virus vaccine against labial
infection of BALB/c mice. Infect Immun 1983, 41: 556–562.
[84] Metcalf JF, Whitley RJ. Protective immunity against herpetic ocular disease in an
outbred mouse model. Curr Eye Res 1987, 6: 167–171.
[85] Rajčáni J, Sabó A, Mucha V, Košťál M, Compel P. Herpes simplex virus type 1 envelope
subunit vaccine not only protects against lethal virus challenge, but also may restrict
latency and virus reactivation. Acta Virol 1995, 39: 37–49.
[86] Myers MG, Bernstein DI, Harrison CJ, Stanberry LR. Herpes simplex virus glycopro‐
tein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in
guinea pigs. Antiviral Res 1988, 10: 83–88.
[87] Blacklaws BA, Krishna S, Minson AC, Nash AA. Immunogenicity of herpes simplex
virus type 1 glycoproteins expressed in vaccinia virus recombinants. Virology 1990,
177: 727–736.
Herpesviridae204
[88] York LJ, Giorgio DP, Mishkin EM. Immunomodulatory effects of HSV2 glycoprotein
D in HSV1 infected mice: implications for immunotherapy of recurrent HSV infec‐
tion. Vaccine 1995, 13: 1706–1712.
[89] Mosko T, Kosovský J, Rezuchová I, Durmanová V, Kúdelová M, Rajcáni J. Expres‐
sion of herpes simplex virus 1 glycoprotein D in prokaryotic and eukaryotic cells. Acta
Virol 2004, 48: 97–107.
[90] Durmanová V, Mosko T, Sapák M, Kosovský J, Rezuchová I, Buc M, Rajcáni J. Efficacy
of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice. Acta
Microbiol Immunol Hung 2006, 53: 459–477.
[91] Long D, Madara TJ, Ponce de Leon M, Cohen GH, Montgomery PC, Eisenberg RJ.
Glycoprotein D protects mice against lethal challenge with herpes simplex virus types 1
and 2. Infect Immun 1984, 43: 761–764.
[92] Roberts PL, Duncan BE, Raybould TJ, Watson DH. Purification of herpes simplex virus
glycoproteins B and C using monoclonal antibodies and their ability to protect mice
against lethal challenge. J Gen Virol 1985, 66: 1073–1085.
[93] Kino Y, Eto T, Nishiyama K, Ohtomo N, Mori R. Immunogenicity of purified glyco‐
protein gB of herpes simplex virus. Arch Virol 1986, 89: 69–80.
[94] Manservigi R, Grossi MP, Gualandri R, Balboni PG, Marchini A, Rotola A, Rimessi P,
Di Luca D, Cassai E, Barbanti-Brodano G. Protection from herpes simplex virus type 1
lethal and latent infections by secreted recombinant glycoprotein B constitutively
expressed in human cells with a BK virus episomal vector. J Virol 1990, 64: 431–436.
[95] Broker M, Abel KJ, Köhler R, Hilfenhaus J, Amann E. Escherichia coli-derived enve‐
lope protein gD but not gC antigens of herpes simplex virus protect mice against a
lethal challenge with HSV-1 and HSV-2. Med Microbiol Immunol 1990, 179: 145–159.
[96] Byars NE, Fraser-Smith EB, Pecyk RA, Welch M, Nakano G, Burke RL, Hayward AR,
Allison AC. Vaccinating guinea pigs with recombinant glycoprotein D of herpes
simplex virus in an efficacious adjuvant formulation elicits protection against vaginal
infection. Vaccine 1994, 12: 200–209.
[97] O'Hagan D, Goldbeck C, Ugozzoli M, Ott G, Burke RL. Intranasal immunization with
recombinant gD2 reduces disease severity and mortality following genital challenge
with herpes simplex virus type 2 in guinea pigs. Vaccine 1999, 17: 2229–2236.
[98] Bourne N, Bravo FJ, Francotte M, Bernstein DI, Myers MG, Slaoui M, Stanberry LR.
Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection
against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis 2003, 187: 542–549.
[99] Manservigi R, Boero A, Argnani R, Caselli E, Zucchini S, Miriagou V, Mavromara P,
Cilli M, Grossi MP, Balboni PG, Cassai E. Immunotherapeutic activity of a recombi‐
nant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig
model. Vaccine 2005, 23: 865–872.
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
205
[100] Durmanová V, Sapák M, Kosovský J, Rezuchová I, Kúdelová M, Buc M, Rajcáni J.
Immune response and cytokine production following immunization with experimen‐
tal herpes simplex virus 1 (HSV-1) vaccines. Folia Microbiol (Praha) 2008, 53: 73–83.
doi: 10.1007/s12223-008-0011-4.
[101] Fotouhi F, Soleimanjahi H, Roostaee MH, Dalimi Asl A. Expression of the herpes
simplex virus type 2 glycoprotein D in baculovirus expression system and evaluation
of its immunogenicity in guinea pigs. Iran Biomed J 2008, 12: 59–66.
[102] Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown
M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova
M, Kingsley S, Bryan J, Casimiro DR, Friedman HM. Protection provided by a herpes
simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital
HSV-2 infection in HSV-1-seropositive guinea pigs. J Virol 2014, 88: 2000–2010. doi:
10.1128/JVI.03163-13.
[103] Awasthi S, Mahairas GG, Shaw CE, Huang ML, Koelle DM, Posavad C, Corey L,
Friedman HM. A dual-modality herpes simplex virus 2 vaccine for preventing genital
herpes by using glycoprotein C and D subunit antigens to induce potent antibody
responses and adenovirus vectors containing capsid and tegument proteins as T cell
immunogens. J Virol 2015, 89: 8497–8509. doi: 10.1128/JVI.01089-15.
[104] Inoue T, Inoue Y, Nakamura T, Yoshida A, Inoue Y, Tano Y, Shimomura Y, Fujisawa
Y, Aono A, Hayashi K. The effect of immunization with herpes simplex virus glyco‐
protein D fused with interluekin-2 against murine herpetic keratitis. Nihon Ganka
Gakkai Zasshi 2001, 105: 223–229.
[105] Mohamedi SA, Heath AW, Jennings R. A comparison of oral and parenteral routes for
therapeutic vaccination with HSV-2 ISCOMs in mice; cytokine profiles, antibody
responses and protection. Antiviral Res 2001, 49: 83–99.
[106] Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G. The influence of adjuvant
on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 1994,
170: 1110–1119.
[107] Shoenfeld Y, Agmont-Levine N. ASIA: autoimmune/inflammatory syndrome in‐
duced by adjuvants. J Autoimmun 2011, 36: 4–8. doi: 10.1016/j.jaut.2010.07.003.
[108] Lavelle EC, Grant G, Pusztai A, Pfüller U, Leavy O, McNeela E, Mills KH, O'Hagan DT.
Mistletoe lectins enhance immune responses to intranasally co-administered herpes
simplex virus glycoprotein D2. Immunology 2002, 107: 268–274.
[109] Cortesi R, Ravani L, Rinaldi F, Marconi P, Drechsler M, Manservigi M, Argnani R,
Menegatti E, Esposito E, Manservigi R. Intranasal immunization in mice with non-ionic
surfactants vesicles containing HSV immunogens: a preliminary study as possible
vaccine against genital herpes. Int J Pharm 2013, 440: 229–237. doi: 10.1016/j.ijpharm.
2012.06.042.
Herpesviridae206
[110] Skoberne M, Cardin R, Lee A, Kazimirova A, Zielinski V, Garvie D, Lundberg A, Larson
S, Bravo FJ, Bernstein DI, Flechtner JB, Long D. An adjuvanted herpes simplex virus 2
subunit vaccine elicits a T cell response in mice and is an effective therapeutic vac‐
cine in guinea pigs. J Virol 2013, 87: 3930–3942. doi: 10.1128/JVI.02745-12.
[111] Rajčáni J, MoškoT, Režuchová, I. Current developments in viral DNA vaccines: shall
they solve the unsolved? Rev Med Microbiol 2005, 15, 1–23.
[112] Cantin EM, Eberle R, Baldick JL, Moss B, Willey DE, Notkins AL, Openshaw H.
Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus
and protection of mice against lethal herpes simplex virus 1 infection. Proc Natl Acad
Sci U S A 1987, 84: 5908–5912.
[113] Willey DE, Cantin EM, Hill LR, Moss B, Notkins AL, Openshaw H. Herpes simplex
virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from
acute and latent infection. J Infect Dis 1988, 158: 1382–1386.
[114] Wachsman M, Aurelian L, Smith CC, Perkus ME, Paoletti E. Regulation of expression
of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their
ability to protect from cutaneous HSV-2 disease. J Infect Dis 1989, 159: 625–634.
[115] Bernstein DI. Effect of route of vaccination with vaccinia virus expressing HSV-2
glycoprotein D on protection from genital HSV-2 infection. Vaccine 2000, 18: 1351–1358.
[116] Natuk RJ, Cooper D, Guo M, Calderon P, Wright KJ, Nasar F, Witko S, Pawlyk D, Lee
M, DeStefano J, Tummolo D, Abramovitz AS, Gangolli S, Kalyan N, Clarke DK, Hendry
RM, Eldridge JH, Udem SA, Kowalski J. Recombinant vesicular stomatitis virus vectors
expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses
and are protective in mouse and guinea pig models of vaginal challenge. J Virol 2006,
80: 4447–4457.
[117] Chiuppesi F, Vannucci L, De Luca A, Lai M, Matteoli B, Freer G, Manservigi R,
Ceccherini-Nelli L, Maggi F, Bendinelli M, Pistello M. A lentiviral vector-based, herpes
simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1
and HSV-2 genital infections. J Virol 2012, 86: 6563–6574. doi: 10.1128/JVI.00302-12.
[118] Daheshia M, Kuklin N, Manickan E, Chun S, Rouse BT. Immune induction and
modulation by topical ocular administration of plasmid DNA encoding antigens and
cytokines. Vaccine 1998, 16: 1103–1110.
[119] Nass PH, Elkins KL, Weir JP. Antibody response and protective capacity of plasmid
vaccines expressing three different herpes simplex virus glycoproteins. J Infect Dis
1998, 178: 611–617.
[120] Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, Lacey CJ.
Prospects for control of herpes simplex virus disease through immunization. Clin Infect
Dis 2000, 30: 549–566.
[121] Baghian A, Chouljenko VN, Dauvergne O, Newmant MJ, Baghian S, Kousoulas KG.
Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
207
immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and
gD. J Med Microbiol 2002, 51: 350–357.
[122] Osorio Y, Cohen J, Ghiasi H. Improved protection from primary ocular HSV-1 infection
and establishment of latency using multigenic DNA vaccines. Invest Ophthalmol Vis
Sci 2004, 45: 506–514
[123] Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, Cohen JI, Straus SE.
Comparative efficacy and immunogenicity of replication-defective, recombinant
glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and
guinea pigs. J Virol 2005, 79: 410–418.
[124] Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, Ebtekar M.
Induction of humoral and cellular immunity against latent HSV-1 infections by DNA
immunization in BALB/c mice. Comp Immunol Microbiol Infect Dis 2007, 30: 197–210.
[125] Bourne N, Milligan GN, Schleiss MR, Bernstein DI, Stanberry LR. DNA immuniza‐
tion confers protective immunity on mice challenged intravaginally with herpes
simplex virus type 2. Vaccine 1996, 14: 1230–1234.
[126] McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of
immunization with DNA encoding herpes simplex virus glycoproteins on HSV-
induced disease in guinea pigs. Vaccine 1997, 15: 857–860.
[127] Strasser JE, Arnold RL, Pachuk C, Higgins TJ, Bernstein DI. Herpes simplex virus DNA
vaccine efficacy: effect of glycoprotein D plasmid constructs. J Infect Dis 2000, 182: 1304–
1310.
[128] Jazayeri M, Soleimanjahi H, Fotouhi F, Pakravan N. Comparison of intramuscular and
footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.
Comp Immunol Microbiol Infect Dis 2009, 32: 453–461. doi: 10.1016/j.cimid.2008.05.002.
[129] Lee HH, Cha SC, Jang DJ, Lee JK, Choo DW, Kim YS, Uh HS, Kim SY. Immunization
with combined HSV-2 glycoproteins B2: D2 gene DNAs: protection against lethal
intravaginal challenges in mice. Virus Genes 2002, 25: 179–188.
[130] Domingo C, Gadea I, Pardeiro M, Castilla C, Fernández S, Fernández-Clua MA, De la
Cruz Troca JJ, Punzón C, Soriano F, Fresno M, Tabarés E. Immunological properties of
a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycopro‐
tein B and glycoprotein D. Vaccine 2003, 21: 3565–3574
[131] Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, McElhiney SP, Wolf MW,
Pompa-de Bruin SJ, Higgins TJ, Ciccarelli RB, Weiner DB. IL-12 gene as a DNA vaccine
adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated
protective immunity against herpes simplex virus-2 challenge. J Immun 1999, 162:
2912–2921.
[132] Cooper D, Pride MW, Guo M, Cutler M, Mester JC, Nasar F, She J, Souza V, York L,
Mishkin E, Eldridge J, Natuk RJ. Interleukin-12 redirects murine immune responses to
Herpesviridae208
soluble or aluminum phosphate adsorbed HSV-2 glycoprotein D towards Th1 and
CD4+ CTL responses. Vaccine 2004, 23: 236–246.
[133] Sin JI, Kim JJ, Boyer JD, Ciccarelli RB, Higgins TJ, Weiner DB. In vivo modulation of
vaccine-induced immune responses toward a Th1 phenotype increases potency and
vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999, 73:
501–509.
[134] Zhu M, Xu X, Liu H, Liu X, Wang S, Dong F, Yang B, Song G. Enhancement of DNA
vaccine potency against herpes simplex virus 1 by co-administration of an interleu‐
kin-18 expression plasmid as a genetic adjuvant. J Med Microbiol 2003, 52: 223–228.
[135] Osorio Y, Ghiasi H. Comparison of adjuvant efficacy of herpes simplex virus type 1
recombinant viruses expressing TH1 and TH2 cytokine genes. J Virol 2003, 77: 5774–
5783.
[136] Lee S, Gierynska M, Eo SK, Kuklin N, Rouse BT. Influence of DNA encoding cyto‐
kines on systemic and mucosal immunity following genetic vaccination against herpes
simplex virus. Microbes Infect 2003, 5: 571–578.
[137] Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. A Vaxfec‐
tin-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and thera‐
peutic use in the guinea pig model of genital herpes. Vaccine 2012, 30: 7046–7051. doi:
10.1016/j.vaccine.2012.09.057.
[138] Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan
S, Koelle DM. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and
immunogenicity in a murine model of genital herpes infection. J Gen Virol 2012, 93:
1305–1315. doi: 10.1099/vir.0.040055-0.
[139] Yan Y, Hu K, Deng X, Guan X, Luo S, Tong L, Du T, Fu M, Zhang M, Liu Y, Hu Q.
Immunization with HSV-2 gB-CCL19 Fusion Constructs Protects Mice against Lethal
Vaginal Challenge. J Immunol 2015, 195: 329–338. doi: 10.4049/jimmunol.1500198.
[140] Bright H, Perez DL, Christy C, Cockle P, Eyles JE, Hammond D, Khodai T, Lang S, West
K, Loudon PT. The efficacy of HSV-2 vaccines based on gD and gB is enhanced by the
addition of ICP27. Vaccine 2012, 30: 7529–7535. doi: 10.1016/j.vaccine.2012.10.046.
[141] Forrester A, Farrell H, Wilkinson G, Kaye J, Davis-Poynter N, Minson T. Construc‐
tion and properties of a mutant of herpes simplex virus type 1 with glycoprotein H
coding sequences deleted. J Virol 1992, 66: 341–348.
[142] McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell
ME, Inglis SC. Protective vaccination against primary and recurrent disease caused by
herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis 1994,
170: 1100–1109.
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
209
[143] Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B. Replication, establishment of
latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion
mutants in rodent models. J Clin Invest 1993, 91: 2837–2843.
[144] Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. A replication-competent,
neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine. J
Virol 2008, 82: 8431–8441. doi: 10.1128/JVI.00551-08.
[145] Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM,
Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. Live attenuated herpes
simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in
neuronal spread. J Virol 2012, 86: 4586–4598. doi: 10.1128/JVI.07203-11.
[146] Keadle TL, Laycock KA, Morris JL, Leib DA, Morrison LA, Pepose JS, Stuart PM.
Therapeutic vaccination with vhs(-) herpes simplex virus reduces the severity of
recurrent herpetic stromal keratitis in mice. J Gen Virol 2002, 83: 2361–2365.
[147] Rajčáni J, Kúdelová M, Oravcová I, Vojvodová A, Košovský J, Matis J. Characteriza‐
tion of strain HSZP of herpes simplex virus type 1 (HSV1). Folia Microbiol (Praha) 1999,
44: 713–719.
[148] Meignier B. Genetically engineered attenuated herpes simplex viruses. Rev Infect Dis
1991, 13: S895–897.
[149] Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-
attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital
herpes than a glycoprotein D subunit vaccine. PLoS One 2011, 6: e17748. doi: 10.1371/
journal.pone.0017748.
[150] de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC,
Shahmanesh M, Kinghorn G, Beutner KR, Patel R, Drehobl MA, Horner P, Kurtz TO,
McDermott S, Wald A, Corey L. A randomized controlled trial of a replication
defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent
genital herpes among immunocompetent subjects. Vaccine 2006, 24: 914–920.
[151] Morrison LA, Knipe DM. Immunization with replication-defective mutants of herpes
simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus
infection. J Virol 1994, 68: 689–696.
[152] Wachsman M, Kulka M, Smith CC, Aurelian L. A growth and latency compromised
herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic
protective activity in guinea pigs. Vaccine 2001, 19: 1879–1890.
[153] Da Costa XJ, Bourne N, Stanberry LR, Knipe DM. Construction and characterization of
a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in
immunization studies in a guinea pig model of genital disease. Virology 1997, 232: 1–
12.
Herpesviridae210
[154] Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. Construction, phenotypic
analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex
virus 2. J Virol 2000, 74: 7963–7971.
[155] Delagrave S, Hernandez H, Zhou C, Hamberger JF, Mundle ST, Catalan J, Baloglu S,
Anderson SF, DiNapoli JM, Londoño-Hayes P, Parrington M, Almond J, Kleanthous
H. Immunogenicity and efficacy of intramuscular replication-defective and subunit
vaccines against herpes simplex virus type 2 in the mouse genital model. PLoS One
2012, 7: e46714. doi: 10.1371/journal.pone.0046714.
[156] Brans R, Yao F. Immunization with a dominant-negative recombinant Herpes Simplex
Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC
Microbiol 2010, 10: 163. doi: 10.1186/1471-2180-10-163.
[157] Casanova G, Cancela R, Alonzo L, Benuto R, Magana Mdel C, Hurley DR, Fishbein E,
Lara C, Gonzalez T, Ponce R, Burnett JW, Calton GJ. A double-blind study of the efficacy
and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections.
Cutis 2002, 70: 235–239.
[158] van Lint AL, Torres-Lopez E, Knipe DM. Immunization with a replication-defective
herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents
ocular disease. Virology 2007, 368: 227–231.
[159] Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI.
Protection from herpes simplex virus (HSV)-2 infection with replication-defective
HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative
guinea pigs. J Infect Dis 2009, 200: 1088–1095. doi: 10.1086/605645.
[160] Stanfield BA, Stahl J, Chouljenko VN, Subramanian R, Charles AS, Saied AA, Walker
JD, Kousoulas KG. A single intramuscular vaccination of mice with the HSV-1 VC2
virus with mutations in the glycoprotein K and the membrane protein UL20 confers
full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2
strains. PLoS One 2014, 9:e109890. doi: 10.1371/journal.pone.0109890.
[161] Zhang X, Castelli FA, Zhu X, Wu M, Maillère B, BenMohamed L. Gender-dependent
HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein
D. Clin Vaccine Immunol 2008, 15: 1436–1449. doi: 10.1128/CVI.00123-08.
[162] Mertz GJ, Peterman G, Ashley R, Jourden JL, Salter D, Morrison L, McLean A, Corey
L. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral
and cellular responses in humans. J Infect Dis 1984, 150: 242–249.
[163] Mertz GJ, Ashley R, Burke RL, Benedetti J, Critchlow C, Jones CC, Corey L. Double-
blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in
persons at high risk for genital herpes infection. J Infect Dis 1990, 161: 653–660
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
211
[164] Langenberg AG, Burke RL, Adair SF, Sekulovich R, Tigges M, Dekker CL, Corey L. A
recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immu‐
nogenicity. Ann Intern Med 1995, 122: 889–898.
[165] Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, Leroux-Roels
G, Van Herck K, Bollaerts A, Dubin G; GlaxoSmithKline Herpes Vaccine Study Group.
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin
Infect Dis 2005, 40: 1271–1281.
[166] Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring
S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G; GlaxoSmithKline Herpes
Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital
herpes. N Engl J Med 2002, 347: 1652–1661.
[167] Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow
RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD; Herpevac
Trial for Women. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med
2012, 366: 34–43. doi: 10.1056/NEJMoa1103151.
[168] Tavares F, Cheuvart B, Heineman T, Arellano F, Dubin G. Meta-analysis of pregnan‐
cy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D
subunit herpes simplex virus vaccine. Vaccine 2013, 31: 1759–1764. doi: 10.1016/
j.vaccine.2013.01.002.
[169] Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, Ginsberg R,
Ciccarelli R, Corey L, Koelle DM. Phase I study of a herpes simplex virus type 2 (HSV-2)
DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free
injection system. Clin Vaccine Immunol 2008, 15: 1638–1643. doi: 10.1128/CVI.00167-08.
[170] Bernard MC, Barban V, Pradezynski F, de Montfort A, Ryall R, Caillet C, Londono-
Hayes P. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2
vaccine candidate HSV529 in mice and guinea pigs. PLoS One 2015, 10: e0121518. doi:
10.1371/journal.pone.0121518.
[171] Kutinová L, Benda R, Kalos Z, Dbalý V, Votruba T, Kvícalová E, Petrovská P, Doutlík
S, Kamínková J, Domorázková E. Placebo-controlled study with subunit herpes
simplex virus vaccine in subjects suffering from frequent herpetic recurrences.
Vaccine 1988, 6: 223–228.
[172] Skinner GR, Turyk ME, Benson CA, Wilbanks GD, Heseltine P, Galpin J, Kaufman R,
Goldberg L, Hartley CE, Buchan A. The efficacy and safety of Skinner herpes simplex
vaccine towards modulation of herpes genitalis; report of a prospective double-blind
placebo-controlled trial. Med Microbiol Immunol 1997, 186: 31–36.
[173] Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, Kost RG, Meier JL,
Sekulovich R, Adair SF. Placebo-controlled trial of vaccination with recombinant
glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes.
Lancet 1994, 343: 1460–1463.
Herpesviridae212
[174] Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AG, Hohman P, Lekstrom J, Cox
E, Nakamura M, Sekulovich R, Izu A, Dekker C, Corey L. Immunotherapy of recur‐
rent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and
B: results of a placebo-controlled vaccine trial. J Infect Dis 1997, 176: 1129–1134.
[175] Laing KJ, Dong L, Sidney J, Sette A, Koelle DM. Immunology in the Clinic Review
Series; focus on host responses: T cell responses to herpes simplex viruses. Clin Exp
Immunol 2012, 167: 47–58. doi: 10.1111/j.1365-2249.2011.04502.x
[176] Laing KJ, Magaret AS, Mueller DE, Zhao L, Johnston C, De Rosa SC, Koelle DM, Wald
A, Corey L. Diversity in CD8(+) T cell function and epitope breadth among persons
with genital herpes. J Clin Immun 2010, 30: 703–722. doi: 10.1007/s10875-010-9441-2.
[177] Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific im‐
mune responses that limit the in vivo persistence of adoptively transferred HSV-TK-
modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006,
107: 2294–2302.
[178] Koelle DM, Liu Z, McClurkan CL, Cevallos RC, Vieira J, Hosken NA, Meseda CA, Snow
DC, Wald A, Corey L. Immunodominance among herpes simplex virus-specific CD8
T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A 2003, 100:
12899–12904.
[179] Chentoufi AA, Binder NR, Berka N, Durand G, Nguyen A, Bettahi I, Maillère B,
BenMohamed L. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from
herpes simplex virus glycoprotein B. J Virol 2008, 82: 11792–11802. doi: 10.1128/JVI.
00692-08
[180] Wang X, Xie G, Liao J, Yin D, Guan W, Pan M, Li J, Li Y. Design and evaluation of a
multi-epitope assembly peptide (MEAP) against herpes simplex virus type 2 infec‐
tion in BALB/c mice. Virol J 2011, 8: 232. doi: 10.1186/1743-422X-8-232.
[181] Liu K, Jiang D, Zhang L, Yao Z, Chen Z, Yu S, Wang X. Identification of B- and T-cell
epitopes from glycoprotein B of herpes simplex virus 2 and evaluation of their
immunogenicity and protection efficacy. Vaccine 2012, 30: 3034–3041. doi: 10.1016/
j.vaccine.2011.10.010.
[182] Muller WJ, Dong L, Vilalta A, Byrd B, Wilhelm KM, McClurkan CL, Margalith M, Liu
C, Kaslow D, Sidney J, Sette A, Koelle DM. Herpes simplex virus type 2 tegument
proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA
immunization and infection. J Gen Virol 2009, 90: 1153–1163. doi: 10.1099/vir.
0.008771-0.
[183] Koelle DM, Frank JM, Johnson ML, Kwok WW. Recognition of herpes simplex virus
type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J
Virol 1998, 72: 7476–7483.
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
213
[184] Novak EJ, Liu AW, Gebe JA, Falk BA, Nepom GT, Koelle DM, Kwok WW. Tetramer-
guided epitope mapping: rapid identification and characterization of immunodomi‐
nant CD4+ T cell epitopes from complex antigens. J Immunol 2001, 166: 6665–6670.
[185] Osorio Y, Mott KR, Jabbar AM, Moreno A, Foster TP, Kousoulas KG, Ghiasi H. Epitope
mapping of HSV-1 glycoprotein K (gK) reveals a T cell epitope located within the signal
domain of gK. Virus Res 2007, 128: 71–80.
[186] Mott KR, Chentoufi AA, Carpenter D, BenMohamed L, Wechsler SL, Ghiasi H. The role
of a glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus on virus replica‐
tion and pathogenicity. Invest Ophthalmol Vis Sci 2009, 50: 2903–2912. doi: 10.1167/
iovs.08-2957.
[187] Haynes JR, Arrington J, Dong L, Braun RP, Payne LG. Potent protective cellular
immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli
heat labile enterotoxin. Vaccine 2006, 24: 5016–5026.
[188] BenMohamed L, Bertrand G, McNamara CD, Gras-Masse H, Hammer J, Wechsler SL,
Nesburn AB. Identification of novel immunodominant CD4+ Th1-type T-cell peptide
epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J
Virol 2003, 77: 9463–9473.
[189] Cooper D, Mester JC, Guo M, Nasar F, Souza V, Dispoto S, Sidhu M, Hagen M, Eldridge
JH, Natuk RJ, Pride MW. Epitope mapping of full-length glycoprotein D from HSV-2
reveals a novel CD4+ CTL epitope located at the transmembrane-cytoplasmic junc‐
tion. Cell Immunol 2006, 239: 113–120.
[190] Chentoufi AA, Zhang X, Lamberth K, Dasgupta G, Bettahi I, Nguyen A, Wu M, Zhu X,
Mohebbi A, Buus S, Wechsler SL, Nesburn AB, BenMohamed L. HLA-A*02:01-
restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus
glycoprotein D. J Immunol 2008, 180: 426–437.
[191] Chentoufi AA, Dasgupta G, Christensen ND, Hu J, Choudhury ZS, Azeem A, Jester JV,
Nesburn AB, Wechsler SL, BenMohamed L. A novel HLA (HLA-A*02:01) transgenic
rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines
against ocular herpes. J Immunol 2010, 184: 2561–2571. doi: 10.4049/jimmunol.0902322.
[192] Posavad CM, Remington M, Mueller DE, Zhao L, Magaret AS, Wald A, Corey L.
Detailed characterization of T cell responses to herpes simplex virus-2 in immune
seronegative persons. J Immunol 2010, 184: 3250–3259. doi: 10.4049/jimmunol.0900722.
[193] Posavad CM, Magaret AS, Zhao L, Mueller DE, Wald A, Corey L. Development of an
interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2.
Vaccine 2011, 29: 7058–7066. doi: 10.1016/j.vaccine.2011.07.028.
[194] Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and haplotypes in the
United States population. Hum Immunol 2007, 68: 779–788.
Herpesviridae214
[195] Koelle DM, Corey L. Herpes simplex: insights on pathogenesis and possible vaccines.
Annu Rev Med 2008, 59: 381–395. doi: 10.1146/annurev.med.59.061606.095540.
[196] Samandary S, Kridane-Miledi H, Sandoval JS, Choudhury Z, Langa-Vives F, Spencer
D, Chentoufi AA, Lemonnier FA, BenMohamed L. Associations of HLA-A, HLA-B and
HLA-C alleles frequency with prevalence of herpes simplex virus infections and
diseases across global populations: implication for the development of an universal
CD8+ T-cell epitope-based vaccine. Hum Immunol 2014, 75: 715–729. doi: 10.1016/
j.humimm.2014.04.016.
[197] Awasthi S, Friedman HM. Status of prophylactic and therapeutic genital herpes
vaccines. Curr Opin Virol 2014, 6: 6–12. doi: 10.1016/j.coviro.2014.02.006.
[198] Wald A, Zeh J, Selke S, Warren T, Ryncarz AJ, Ashley R, Krieger JN, Corey L.
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropos‐
itive persons. N Engl J Med 2000, 342: 844–850.
[199] Khan AA, Srivastava R, Spencer D, Garg S, Fremgen D, Vahed H, Lopes PP, Pham TT,
Hewett C, Kuang J, Ong N, Huang L, Scarfone VM, Nesburn AB, Wechsler SL,
BenMohamed L. Phenotypic and functional characterization of herpes simplex virus
glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic
and asymptomatic individuals with ocular herpes. J Virol 2015, 89: 3776–3792. doi:
10.1128/JVI.03419-14.
Herpes Simplex Virus 1 and 2 Vaccine Design: What can we Learn from the Past?
http://dx.doi.org/10.5772/64447
215

